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Low-cost, High-contrast, and Miniature Optical Imaging Systems for Clinical 
Applications 
Mohsen Erfanzadeh, PhD 
University of Connecticut, 2018 
Reducing the cost and size and enhancing the contrast of optical imaging systems 
improve their potentials for clinical applications. In this dissertation, we describe our 
endeavors towards development of low-cost and compact photoacoustic microscopy and 
spatial frequency domain imaging systems as well as improvement of photoacoustic 
tumor imaging using a specifically designed photoacoustic contrast agent.  
Chapters two and three focus on the development of low-cost and compact laser diode 
based photoacoustic microscopy systems. We first provided an improvement in light 
delivery of laser diode based photoacoustic microscopy systems that enables imaging 
biological tissue with high signal to noise ratio. We then developed a laser scanning laser 
diode based photoacoustic microscopy system that provides substantial improvement of 
imaging speed and eliminates the need for mechanical scanning of the sample, hence 
improving the potentials of low-cost and compact laser diode based photoacoustic 
microscopy for clinical applications.  
Chapter four describes synthesis and evaluation of a monomeric porphyrin-based 
photoacoustic contrast agent for improvement of in vivo tumor imaging. Absorption in near 
infrared wavelength range, solubility, stability, nontoxicity, and high photoacoustic 
generation efficiency of the dye were demonstrated. The contrast agent was evaluated 
for enhancing the photoacoustic images of implanted murine tumors revealing a multi-
fold stronger enhancement and a slower washout compared to the benchmark FDA 
approved indocyanine green (ICG) dye. Favorable filtration and tumor accumulation of 
the dye further demonstrated its potential as a photoacoustic contrast agent for in vivo 
tumor imaging.  
Finally, chapter 5 describes development of a very low-cost, handheld, and multispectral 
spatial frequency domain imaging system that incorporates nine different light emitting 
diodes and all illumination and detection optical components in a small 3D-printed probe. 
The system performance was evaluated on biological tissue to assess its potentials.
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1. Introduction 
Optical imaging is the term referred to imaging techniques that utilize light to non-
invasively probe the tissue [1]. Upon interaction with biological tissue, optical energy is 
both scattered and absorbed. Some optical imaging modalities make use of light 
scattering (e.g. optical coherence tomography (OCT) [2]), some utilize light absorption 
(e.g. photoacoustic imaging (PAI) [3]), and some consider both scattering and absorption 
(e.g. spatial frequency domain imaging (SFDI) [4]). Optical imaging can probe shallower 
targets (mm range depth) with high resolution (e.g. OCT and photoacoustic microscopy 
(PAM)) or deeper targets (cm range depth) at lower resolution (e.g. photoacoustic 
tomography (PAT) and diffuse optical tomography (DOT) [5]). Different modalities of 
optical imaging have been used in various applications including, but not limited to, 
dermatology [6], ophthalmology [7], and several branches of oncology [8–11].  
Photoacoustic microscopy, photoacoustic tomography, and spatial frequency domain 
imaging are among the rapidly growing modalities in optical imaging with various 
applications including the diagnosis and characterization of several cancer types 
including ovarian, colorectal, cervical, and breast cancer. In this dissertation we will 
discuss our efforts towards improving these imaging modalities and enhancing their 
potentials for clinical applications. The dissertation is structured as below.  
Chapter 1 includes the introduction to the dissertation and general background about 
photoacoustic imaging and spatial frequency domain imaging. 
Chapter 2 discusses our first efforts towards improvement and evaluation of a low-cost 
laser diode based photoacoustic microscopy system to be capable of imaging ovarian 
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tissue. Here, using an efficient light delivery method, we managed to increase the signal 
to noise ratio of photoacoustic imaging with a low-cost laser diode as the excitation 
source. The system showed capability of imaging vasculature under the surface of 
ovarian tissue showing the potential for imaging epithelial ovarian cancer. This system, 
however, still used mechanical scanning of the sample and required multiple averaging 
in data acquisition. Therefore, as is discussed in chapter 3, we developed a laser 
scanning laser diode based photoacoustic microscopy system eliminating mechanical 
scanning of the sample and providing significant improvement in imaging speed. 
In chapter 3, we discuss development of the laser scanning laser diode photoacoustic 
microscopy system. This system provides a significant improvement in the imaging speed 
and also does not require any mechanical scanning of the sample, therefore improving 
the potential of the system for clinical applications. Here we show that this system is also 
capable of imaging thin vasculature under the surface of ovarian tissue and is therefore 
able to image and characterize epithelial ovarian cancer.   
Chapter 4 discusses our collaborative effort with Professor Christian Bruckner’s research 
laboratory at chemistry department of the University of Connecticut to develop and 
evaluate the performance of a specifically designed photoacoustic contrast agent in order 
to improve in vivo photoacoustic tomography of tumor angiogenesis. Here we 
demonstrate the high photoacoustic generation efficiency of the dye, the multi-fold 
enhancement of in vivo photoacoustic images of murine tumors upon injection of the 
contrast agent, and also evaluate the washout and accumulation of the dye. 
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In chapter 5, we discuss our efforts for developing a very low-cost, handheld, and 
multispectral spatial frequency domain imaging prototype with potentials for ex vivo 
cancer characterization.  
Finally, chapter 6 provides a summary of the endeavors discussed in this dissertation.  
In the continuation of this chapter, we will provide a short background about the optical 
imaging modalities discussed in this dissertation. First, we will explain photoacoustic 
imaging which can be divided into two subcategories of photoacoustic microscopy and 
photoacoustic tomography and then we will explain spatial frequency domain imaging. 
1.1. Photoacoustic imaging 
Photoacoustic imaging, also known as optoacoustic imaging, is a hybrid imaging modality 
based on the thermoelastic induction of acoustic waves as a result of the absorption of 
pulsed or modulated optical energy [3,12–14]. In photoacoustic imaging, absorption of 
the optical energy with a short duration results in a local temperature rise that in turn 
causes the generation of mechanical pressure which propagates as mechanical waves, 
i.e. ultrasound wave. The generated photoacoustic signal can be detected by different 
means of ultrasound transduction, either with conventional contact transducers or in non-
contact fashion [15,16]. Figure 1.1 shows a schematic of the generation and detection of 
photoacoustic signals.  
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Figure 1.1 Schematic of generation and detection of photoacoustic signals. Schematic is reproduced by the author, 
however the original idea of the schematic is taken from Ref [17].  
 
Photoacoustic imaging can be categorized into two sub-modalities: photoacoustic 
microscopy for imaging in millimeter depth range at micrometer resolution and 
photoacoustic tomography for imaging in centimeter depth range but with lower resolution 
compared to photoacoustic microscopy. In PAM, either light or the ultrasound signal are 
focused, leading to optical resolution PAM (OR-PAM) or acoustic resolution PAM (OR-
PAM). OR-PAM provides higher resolution compared to AR-PAM, while AR-PAM can 
generally image deeper targets compared to OR-PAM. In PAM, ultrasound signal is 
detected point-by-point via raster scanning the sample or steering the light and/or the 
ultrasound signal, while in PAT, array ultrasound transducers are used to form two-
dimensional images, similar to ultrasound imaging [3,17]. Figure 1.2 shows a schematic 
comparing photoacoustic microscopy and photoacoustic tomography.  
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Figure 1.2 Comparison of photoacoustic microscopy and photoacoustic tomography. Schematic is reproduced by the 
author, however the original idea of the schematic is taken from Ref [17]. 
Because photoacoustic signal is generated as a result of light absorption, tissue 
constituents with higher absorption compared to the background tissue in the excitation 
wavelength act as the source of contrast in photoacoustic imaging. In the visible and near 
infrared wavelength ranges hemoglobin acts as the endogenous contrast source of 
photoacoustic imaging [18], as a result photoacoustic imaging has shown potential in 
detection and monitoring of various cancer types by mapping tumor angiogenesis [19,20], 
which is the irregular growth of blood vasculature around the tumor [21]. 
Three chapters of this dissertation focus on photoacoustic imaging. In chapters 2 and 3, 
we discuss our efforts in developing laser diode based photoacoustic microscopy systems 
in order to reduce the cost and size of PAM systems and make them more suitable for 
clinical settings. Chapter 4 discusses synthesis and evaluation of an exogenous 
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photoacoustic contrast agent specifically designed to enhance imaging of tumor 
angiogenesis in vivo.  
1.2. Spatial frequency domain imaging 
Spatial frequency domain imaging is a large-field-of-view imaging modality that can 
provide quantitative information about optical absorption and scattering properties of 
tissue [4,22]. In this method, tissue is illuminated with spatially modulated light (often 
sinusoidal) and the diffused backscattered light is detected by a camera and the optical 
properties of the tissue can be estimated using the diffuse reflected light from the target 
and a calibrated phantom.. Figure 1.3 shows a schematic of spatial frequency domain 
imaging. 
 
Figure 1.3 Schematic of SFDI. Tissue is illuminated with spatially modulated light and the diffuse reflected light is 
detected by a camera. 
The spatial sinusoidal pattern can be represented as: 
In =  I0 sin(2πfxx + 𝜑𝑛)                                                   (1.1) 
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where I0 is the source amplitude, fx is the spatial frequency, and φn is the illumination 
phase. Tissue is illuminated with three phase shifted patterns (0, 2π/3, and 4π/3) and the 
DC and AC components (f = 0 and fx) are extracted as: 
MDC =
I1+I2+I3
3
                                                  (1.2) 
MAC =
√2 
3
[ (I1 − I2)
2 + (I3 − I2)
2 + (I3 − I1)
2]
1
2                       (1.3) 
The DC and AC components of the diffuse reflected light from the target are compared to 
the DC and AC components of a calibrated phantom imaged in the same conditions as 
the target. Moreover, the diffuse reflectance of the calibrated phantom (for f = 0 and fx) is 
calculated from the forward model of spatially modulated light diffusion approximation or 
Monte Carlo simulations [4]. The calibrated diffuse reflectance of the target is found as: 
𝑅𝑑 =
𝑀
𝑀(𝑟𝑒𝑓)
 𝑅𝑑(𝑟𝑒𝑓)                                             (1.4) 
Here, Rd is the diffuse reflectance of the target, Rd (ref) is the calculated diffuse reflectance 
for the homogenous reference phantom, M is the measured (for f = 0 and fx) diffuse 
reflected light from the target, and M(ref) is the measured (for f = 0 and fx) diffuse reflected 
light from the reference phantom. Therefore two Rd values for DC (f = 0) and AC (f = fx) 
components are measured. Finally, a lookup table that relates different values of Rd with 
absorption coefficient (μa) and reduced scattering coefficient (μ’s) values is used to 
reconstruct for μa and μ’s of the target at each pixel of the image [4].  
Because optical properties of tissue vary in the healthy and diseases stages, spatial 
frequency domain imaging can be used for disease diagnosis and characterization. This 
method has been used for characterization of different cancer types including ovarian and 
breast cancer [9,23]. In chapter 5 of this dissertation, we discuss our efforts in developing 
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a very low-cost, handheld, and multispectral spatial frequency domain imaging prototype 
suitable for ex vivo cancer characterization.  
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2. Improvement and evaluation of a laser diode photoacoustic microscopy 
system for ovarian tissue imaging 
2.1. Introduction 
Photoacoustic imaging (PAI) is based on the thermoelastic induction of acoustic waves 
in a medium due to the optical absorption of pulsed laser or modulated light [1–3]. 
Photoacoustic imaging is capable of mapping blood vasculature due to the higher optical 
absorption of hemoglobin in the visible and near infrared (NIR) range in comparison to 
other tissue chromophores [4]. Angiogenesis is a significant factor for cancer 
development [5], therefore photoacoustic imaging has been utilized for diagnosis and 
characterization of various cancer types such as breast and ovarian cancer [6–9]. 
Photoacoustic microscopy (PAM) can provide high resolution images of 
microvasculature. Clinical applications of PAM are limited due to the use of expensive 
and bulky pulsed laser sources [10]. High power pulsed laser diodes (PLD) can be 
suitable substitute light sources for PAM [10–13]. However, multiple active elements in 
high power PLDs and intrinsic anisotropy of the PLD beam challenge maintaining low-
loss focusing of light [14], hence limiting the applications of laser diode based PAM 
systems. Here, a laser diode based optical resolution photoacoustic microscopy system 
that utilizes a near infrared PLD and a low-loss optical setup is presented. Combination 
of aspherical and cylindrical lenses enables energy efficient collimation and focusing of 
light. Images of human hairs, polyethylene tubes filled with rat blood, mouse ear ex vivo, 
and porcine ovary ex vivo are presented to demonstrate the feasibility of the system for 
imaging ovarian tissue. 
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2.2. Methods 
The configuration of the laser diode based photoacoustic microscopy system is illustrated 
in Figure 2.1. A 905 nm pulsed laser diode (Laser components, 905D5S2L3J08R) with 
650 W maximum output peak power is used as the excitation source. The PLD is placed 
in a collimation tube where light passes an aspheric lens (Thorlabs, C330TMD-B) for 
collimation. The optimal choice of the collimating lens and the position of the laser diode 
with respect to the lens is determined using Zemax simulations (Zemax LLC). The 
stacked PLD is comprised of 10 active regions placed in two columns, therefore the output 
beam after collimation is made of two columns each made of five rectangular bars. Each 
separate bar is collimated by the aspheric lens, however because the active areas are 
placed in various positions with respect to the optical axis of the lens [14] they will 
separate from one another in two perpendicular directions after passing the collimating 
lens. Therefore using a microscope objective for light focusing introduces a significant 
energy loss [14], However obtaining reasonable focusing by conventional lenses requires 
further collimation of the beam. Two perpendicular cylindrical lenses (Thorlabs, 
LJ1212L1-B and LJ1125L1-B) are used to collimate the light in two perpendicular 
directions. The collimated beam forms a rectangle of approximately 15 mm by 10 mm 
400 millimeters away from the source. The light is then focused on the sample by an 
aspheric lens (Edmund optics, 66-020) with a numerical aperture of 0.71. The proposed 
focusing method introduces 6.8 dB less loss in comparison to the previously reported 
system [10] when using similar PLDs. A function generator provides the PLD driver (Laser 
components, LSP40) and the data acquisition (DAQ) board with synchronized 1 KHz 
repetition rate TTL (Transistor-Transistor Logic) pulses. Photoacoustic signal is coupled 
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from the sample to the ultrasound transducer (Echo, BI933, 3.5 MHz center frequency) 
by ultrasound (US) gel. The signal is sampled by the data acquisition board with 128 
averaging after being amplified by the Panametrics receiver with a gain of 59 dB. No pre-
amplification of the signal is required due to the low-loss collimation and focusing of light.  
 
Figure 2.1 Schematics of the laser diode based photoacoustic microscopy system 
2.3. Results and discussion 
The resolution of the proposed PAM system was measured to be approximately 40 
micrometers by imaging a sharp blade edge. The edge spread function (ESF) was 
obtained from the one-dimensional cross section profile of the maximum amplitude 
projection (MAP) image. The best fit of an error function on the ESF was obtained. The 
full width at half maximum (FWHM) of the line spread function (LSF), which is the first 
derivative of the edge spread function, represents the resolution of the system [15,16]. 
The one-dimensional cross section measurement, the corresponding ESF, and the 
corresponding LSF are presented in Figure 2.2. Furthermore black human hairs were 
imaged to test the imaging capability of the system. The maximum amplitude projection 
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image of crossing hairs is shown in Figure 2.3. The peak to peak photoacoustic signal to 
noise ratio (SNR) for imaging this phantom was 27.6 dB. 
 
Figure 2.2. The edge response measurement from a sharp blade edge, the fitted edge spread function, and the 
corresponding line spread function. The resolution is measured to be approximately 40 micrometers. 
 
Figure 2.3. PAM image of crossing human hairs. The peak to peak photoacoustic SNR of 27.6 dB was measured for 
imaging this phantom. 
To further study the feasibility of the system in imaging biological tissues, phantoms made 
of polyethylene tubing filled with rat blood were imaged. The PAM image of two blood 
filled tubes placed next to each other is depicted in Figure 2.4A. The tube on the left has 
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an inner diameter of 0.58 mm and an outer diameter of 0.985 mm. The tube on the right 
has an inner and outer diameter of 0.38 mm and 1.09 mm, respectively.  The normalized 
one-dimensional cross section profile of the image along the dotted line is shown in Figure 
2.4B. The FWHM of the tube images are measured to be approximately 0.625 mm and 
0.42 mm for the tube on the left and right, respectively. Possible sources of error could 
be the generation of ultrasound from the tube wall and non-ideal positioning of the tubes. 
The peak to peak photoacoustic SNR for this phantom is 32.7 dB. The previously reported 
system using a microscope objective for focusing the light from a PLD provided a SNR of 
12 dB for similar phantoms [10], indicating the reduction of optical loss and a higher signal 
to noise ratio in the current system. 
 
Figure 2.4 A. PAM image of two tubes with inner diameters of 0.58 mm and 0.38 mm. B. One-dimensional cross 
section profile of the image along the dotted line. FWHM of the tubes on the left and right are 0.625 mm and 0.42 
mm, respectively. 
PAM images of mouse ear ex vivo were acquired to demonstrate the feasibility of the 
system for imaging biological samples. The PAM image and the photograph of the mouse 
ear are presented in Figure 2.5A and 2.5B, respectively. The peak to peak photoacoustic 
signal to noise ratio of this image is approximately 22 dB. The signal to noise ratio of this 
image is enhanced compared to the previously reported NIR laser diode based PAM 
image of similar biological tissue [10,13]. 
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Figure 2.5 A. PAM image of a mouse ear. B. Photograph of the mouse ear. 
To investigate the feasibility of the proposed system in imaging ovarian tissue and 
diagnosis of ovarian cancer, porcine ovary samples were imaged ex vivo. The PAM image 
and the photograph of the porcine ovary are illustrated in Figure 2.6A and 2.6B, 
respectively. The imaged vasculature was located well below the surface and was not 
visible for photography until after the sample was dried out. Therefore the proposed PAM 
system is capable of imaging the vasculature below the surface of the ovary. The peak to 
peak photoacoustic signal to noise ratio of this image is approximately 25 dB. The 
maximum laser intensity on the tissue from this system is estimated to be approximately 
2 mJ/cm2, which is far below the maximum permissible exposure (MPE) for this 
wavelength according to the American National Standards Institute (ANSI) safety 
standard [17].  These results suggest the feasibility of using the proposed laser diode 
based PAM system for imaging ovarian tissue and potentially diagnosis and 
characterization of ovarian cancer.  
2. LDPAM 
19 
 
Figure 2.6 A. PAM image of porcine ovary. B. Photograph of the porcine ovary. The arrow points to the imaged area. 
 
2.4. Summary 
A laser diode based photoacoustic microscopy system with a low-loss focusing method 
is presented for imaging biological tissues. The difficulty of providing low-loss focusing of 
high power PLDs is addressed by collimating the light with an aspheric lens as well as 
two perpendicular cylindrical lenses and focusing the light with a 0.71 NA aspheric lens. 
Light loss compared to the previously reported system is decreased by 6.8 dB. Due to the 
reduction in optical loss the need of a pre-amplifier, which can introduce wideband noise 
to the signal, is eliminated. The resolution of the system is measured to be around 40 
micrometers by using the edge spread function estimation of imaging a sharp blade. 
Images of human hairs, polyethylene tubing filled with rat blood, mouse ear ex vivo, and 
porcine ovary ex vivo are provided to demonstrate the ability of the system in imaging 
biological samples. The results indicate the feasibility of the proposed low-cost laser diode 
based PAM system for imaging ovarian tissue and possibly diagnosis and 
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characterization of ovarian cancer. The low-loss optical system for collimation and 
focusing brings about the possibility of utilizing much less averaging and therefore faster 
imaging. Furthermore, the flexibility of having a collimated beam in a long range enables 
laser scanning photoacoustic microscopy in order to significantly increase the imaging 
speed. In the next chapter we will explain our efforts towards development of a laser 
scanning laser diode photoacoustic microscopy system. 
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3. Laser scanning laser diode photoacoustic microscopy system 
3.1. Introduction 
Photoacoustic imaging (PAI) is a fast emerging imaging modality based on the 
thermoelastic induction of acoustic waves as a result of the absorption of pulsed or 
modulated optical energy [1–4]. Optical energy provides the excitation source and the 
induced acoustic waves are detected via ultrasound transduction [1]. Therefore, the 
difference in the absorption of tissue constituents provides the optical contrast in PAI.  
Photoacoustic imaging is capable of mapping blood vasculature due to the higher 
absorption of hemoglobin compared to other tissue constituents in the visible and near 
infrared (NIR) wavelength ranges [1,5]. Angiogenesis, which is the irregular growing of 
vasculature in the tumor area, is a significant indicator of cancer development [6–10].  
Hence, photoacoustic tomography (PAT) and photoacoustic microscopy (PAM) have 
been utilized in oncology [11,12] for cancer detection and treatment monitoring via 
mapping tumor angiogenesis in breast [13,14], prostate [15–17], skin [18–20], thyroid 
[21,22], colorectal [23–25], pancreatic [25], cervical [26], and ovarian cancer [27–32].  
Out of the 30 different types of ovarian cancer, almost 90% of the cases are epithelial 
ovarian cancer, which originates from the cells covering the outer surface of the ovary. 
Unfortunately only about 30 percent of epithelial ovarian cancer cases are diagnosed at 
early stages [10,33,34].  Currently, the standard of care is removal of ovaries of high risk 
patients. This procedure, however, increases the mortality rate of young women [35], and 
therefore, the development of methods to reduce unnecessary surgeries is critical. Given 
the significance of angiogenesis in epithelial ovarian cancer [8], Wang et al. demonstrated 
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the potential of a PAM image feature extraction algorithm for classification of normal and 
malignant ex vivo ovarian tissues [27].  
However, that PAM system included a solid-state laser system (i.e. Ti-Sapphire laser 
pumped by a second harmonic Nd:YAG laser (LT2211 and LS-2134, Symphotics TII 
Corp, Camarillo, CA)) and a high precision 3-D linear motor [27]. The system was not 
only expensive and bulky but also slow on data acquisition. Solid-state lasers can be 
more compact and fast; however, the cost is still high with prices in the range of $15K to 
$40K. Low-cost and compact PAM systems will facilitate the transition from laboratory 
tools to clinical devices. There are many clinical applications that could potentially benefit 
from low cost, compact and fast photoacoustic microscopy and endoscopy systems such 
as ovarian cancer [27], skin cancer [18–20], cervical cancer [26,36,37], and colon cancer 
[23–25] detection and diagnosis. The importance of developing low-cost, compact, and 
fast photoacoustic imaging systems for enhancing the clinical applicability of 
photoacoustic imaging in oncology has been emphasized by other researchers as well 
[11]. Low-cost photoacoustic imaging systems can also encourage biomedical 
photoacoustic research in developing countries. Additionally, considering the applications 
of PAI in oncology and the importance of access to affordable medical devices in low-
income countries as stated by the World Health Organization (WHO) compendium of 
innovative health technologies for low-resource settings, low-cost PAI systems can 
potentially benefit the realization of Universal Health Coverage (UHC) [38].  
High-power pulsed laser diodes (PLD) have been used as low-cost and compact 
substitutes for light sources both in PAM and PAT [39–46]. Wang et al. presented a low-
cost laser diode-based PAM system with a 905 nm PLD as the excitation source.  
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However, the signal-to-noise ratio (SNR) and imaging quality of the system was limited 
mainly due to the optical energy loss in a 60x microscope objective [41,42].  Moreover, 
the need for 128 signal averaging limited the imaging speed of the system. Zeng et al. 
demonstrated a laser diode based PAM system with a 405 nm PLD as the excitation 
source which required 512 averaging and had a low imaging speed [43]. Li et al. 
presented a laser diode based PAM system with a Blu-ray DVD pickup head as the 
excitation source [45]. This system also required 3000 times averaging for imaging 
biological tissues. We previously reported a method to obtain a low-loss collimation and 
focusing for a 905 nm high power PLD that enabled obtaining PAM images of porcine 
ovarian tissue [42]. However, the aforementioned system also suffered from a low 
imaging speed. Moreover, the laser diode based PAM systems mentioned above require 
mechanical scanning of the sample which limits potential clinical applications. 
Moving toward clinical in vivo PAM applications requires rapid image acquisition. 
However, rapid image acquisition also benefits ex vivo clinical and research applications. 
This is because incised ovaries should be fixed in formalin soon after the incision in order 
to preserve the freshness for histology, thus providing only a short imaging time window 
after the surgery. Faster ex vivo imaging will hence better preserve the sample freshness 
and morphological information prior to formalin fixation [47]. Here, for the first time to the 
best of our knowledge, we present a fast laser scanning laser diode-based photoacoustic 
microscopy system. No averaging is used for obtaining the images. The imaging speed 
is 370 A-lines per second. The long-reach and low-loss collimation of the PLD beam 
needed for laser scanning is achieved using a combination of aspheric and cylindrical 
lenses. Two galvanometer scanning mirrors perform the two-dimensional scanning of the 
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beam across an aspheric focusing lens, hence no need for mechanical scanning of the 
sample. Photoacoustic microscopy images of human hairs, ex vivo mouse ear, and ex 
vivo porcine ovary are presented to demonstrate the feasibility of the proposed system 
for imaging and characterizing biological tissues. The capability of imaging the thin 
vasculature on porcine ovarian tissue suggests the potential of the proposed system for 
characterization and classification of ovarian tissue [27] with a low-cost and fast PAM 
system. 
3.2. Methods 
3.2.1. Laser scanning laser diode photoacoustic microscopy setup 
The schematic of the laser diode based photoacoustic microscopy system is depicted in 
Figure 3.1A. A 905 nm (± 10 nm), 325 W maximum output peak power pulsed laser diode 
(Laser components, 905D5S3J08S) is utilized as the excitation source. The laser is 
pulsed by a PLD driver (D, PicoLas LDP-V 240-100 V3) with 50 ns pulsewidth (Figure 
3.1B).  
3. LSLDPAM 
28 
 
Figure 3.1 A. Schematic of the laser scanning laser diode based photoacoustic microscopy system. The dashed 
arrows represent trigger and control signals and the solid arrows represent PA signal transfer. B. Pulsewidth of the 
PLD light is ~50 ns. 
In order to perform laser scanning, the PLD light has to be well collimated for a reasonably 
large distance. However, the multiple active elements in high power stacked PLDs and 
the intrinsic anisotropy of their beam [42,48] are challenges for maintaining a low-loss 
collimation of the light. The PLD used in this system has a 200 × 440 µm emitting area. It 
consists of five active areas, each 200 μm wide. The active areas are stacked vertically 
with 110 μm vertical separation between consecutive ones. The PLD is first placed inside 
a collimation tube (CT) with an aspheric lens (A1, Thorlabs, A230TM-B) in order to 
improve the collimation. This, however, is not sufficient because of the short focal length 
of the lens, and the rather large vertical separation between the active elements and beam 
divergence angle. Therefore, to further improve the collimation, four cylindrical lenses are 
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utilized. Two of these lenses (C1 and C3, Thorlabs, LJ11878L2-B and LJ1821L1-B, 
respectively) act as a Keplerian beam expander in the slow axis direction, and the other 
two (C2 and C4, Thorlabs, LJ1212L1-B and LJ1105L1-B, respectively) act as a Keplerian 
beam expander in the fast axis direction. Figure 3.1A only shows the changes in the beam 
in the fast axis direction as the slow axis direction has no vector components in the plane 
of this two-dimensional illustration. After passing through C4 the entire beam maintains 
its initial 17 × 12 mm size for more than 30 cm until it reaches the scanning mirrors and 
the focusing lens. Two galvanometer scanning mirrors (GM, GSI Group, G330) are used 
to scan the beam across a 1- inch diameter aspheric lens (A2) with a numerical aperture 
(NA) of 0.71 (Edmund optics, 66-020) which focuses the beam on the sample (S). The 
generated photoacoustic (PA) signal is detected by an unfocused ultrasound transducer 
(Tr) with a center frequency of 3.5 MHz and a bandwidth of 60% (Echo, BI933). 
Ultrasound gel (G) is used for coupling the PA signal between the sample and the 
transducer. The transducer and sample are placed on a three-dimensional stage (St) for 
positioning of the sample. 
3.2.2. Data acquisition and processing 
The PA signal is amplified by an ultrasound pulser and receiver (PR, Panametrics, 
5072PR) with 59 dB gain and is digitized by a 65 MHz, 14-bit data acquisition (DAQ) card 
(Gage-applied, GS8325). The mirrors and the data acquisition card are synchronized by 
the DAQ PC. A 16-bit multifunction data acquisition card (National Instruments, PCIe 
6251) provides a finite number of 1 KHz trigger pulses to a function generator (FG) that 
feeds the PLD driver. The same trigger signal is sent to the ultrasound receiver. The B-
scan signal of the x-axis mirror is a ramp signal from the multifunction DAQ card and it 
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starts and finishes in synchrony with the beginning and end of the trigger pulse train. A-
lines are acquired via a multiple acquisition scheme. A-line data are triggered by the 
trigger output of the ultrasound receiver, stored in the circular buffer of the Gage DAQ 
card, and transferred to the PC after a B-scan is finished. The y-axis mirror moves in a 
step-wise fashion after the B-scan data acquisition and saving is performed. Control, data 
acquisition, and signal processing to form maximum intensity projection (MIP) images are 
performed in a single code in MATLAB (MathWorks, Natick, Massachusetts, USA). No 
averaging is performed on the A-line signals. A MATLAB built-in moving average filter is 
performed on the raw A-line signals to slightly remove the high frequency noise (higher 
than 8 MHz) and improve the SNR. The final image undergoes a MATLAB built-in median 
filter. The final imaging speed is approximately 370 A-lines are per second. Therefore, for 
instance, a 500 × 200-pixel image can be acquired and displayed in approximately four 
and a half minutes. 
3.3. Results 
3.3.1. Lateral resolution 
The maximum field of view was measured by imaging targets of known sizes and 
comparing the size of their image to the field of view. A maximum field of view of 
approximately 4.6 mm × 3.7 mm ±0.3 mm was obtained.  Several measurements were 
performed and the average value is reported. 
The lateral resolution was measured to be approximately 21 µm using edge spread 
function estimation. The edge of a high contrast target (black tape) was imaged and the 
one-dimensional cross-sectional profile of the image was fitted by an error function, which 
is considered as the edge spread function (ESF). The first derivative of the ESF 
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represents the line spread function (LSF) and the full-width-at-half-maximum (FWHM) of 
the LSF represents the lateral resolution [49,50].   Figure 3.2A shows the PAM image of 
the edge of the high contrast target. Figure 3.2B depicts the measured edge response 
along the dashed line in Figure 3.2A, the fitted ESF, and the corresponding LSF. The 
pixel size in Figure 3.2A is 0.125 × 6.7 μm in horizontal and vertical directions, 
respectively. The pixel sizes are governed by the scanning area and the number of A-
lines per B-line for the horizontal direction and the number of B-lines for the vertical 
direction.  
 
Figure 3.2 A. PAM image of the edge of a high contrast target. The color bar represents normalized PA amplitude. B. 
The one-dimensional cross-sectional profile of the image along the dashed line, the ESF, and the LSF. FWHM of the 
LSF is approximately 21 µm. 
 
 
 
3.3.2. Axial resolution 
The theoretical axial resolution as derived from the ultrasound transducer is given as 0.88 
c/B, where c is the speed of sound in tissue (~1540 m/s) and B is the bandwidth of the 
transducer [51].With a 3.5 MHz central frequency and 60% bandwidth (corresponding to 
4.1 MHz), the theoretical acoustic axial resolution is ~331 μm. Figure 3.3A shows the 
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PAM image of a thin human hair. The pixel size in Figure 3.3A is 0.836 × 2.1 μm in 
horizontal and vertical directions, respectively. As shown in Figure 3.3B, FWMH of the 
one-dimensional cross-section of the image along the dashed line is approximately 35 
μm. Figure 3.3C shows the A-line signal from the thin hair target and its envelope obtained 
from Hilbert transformation. FWHM of the envelope is ~220 ns, corresponding to an ~339 
μm axial resolution [51], which is very close to the theoretical value. Due to the limited 
axial resolution of the transducer compared to the lateral resolution, only 2D images are 
presented in this report. It should be noted that with higher pulsewidths, axial resolutions 
larger than the theoretical value were obtained, and this would further limit the ability to 
separate targets at different depths.  
 
Figure 3.3 A. PAM image of a thin human hair. The color bar represents normalized PA amplitude. B. One 
dimensional cross-sectional profile of the image in (A) along the dashed line shows ~35 μm thickness. C. A-line 
signal from the hair and the corresponding envelope. FWHM of the envelope is ~220 ns, corresponding to ~339 µm 
axial resolution. 
3.3.3. Depth of penetration 
In order to assess the penetration depth, a black human hair is inserted approximately 
two millimeters below the surface of a chicken breast and another black human hair is 
inserted just below the surface to serve as the reference point for depth measurement. 
Figure 3.4A and 3.4B show the side and overhead views of the chicken breast piece, 
respectively. Figure 3.4C shows the maximum intensity projection image of the two hairs 
and Figure 3.4D shows the B-line image along the dashed line in Figure 3.4C. The 2-mm 
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axial distance between the hairs is apparent in Figure 3.4D and the SNR, 20 log (Vsignal 
/ Vnoise), of both hairs is slightly higher than 6 dB. It should also be noted that the hair 
close to the surface (on the left side of the image in Figure 3.4C) appears thicker than the 
deeper hair (on the right side of the image in Figure 3.4C) because the focal spot is set 
to be closer to the 2-mm deep hair and the hair close to the surface is out of focus 
considering the 0.71 NA of the focusing lens. The pixel size in Figure 3.4C is 3.1 × 4.2 
μm in horizontal and vertical directions, respectively. The pixel size in Figure 3.4D is 3.1 
× 23.6 μm in the horizontal and axial directions, respectively. The axial pixel size is 
governed by the 65 MHz sampling of the data acquisition card and assuming 1540 m/s 
speed of sound in the tissue.  
 
Figure 3.4 A. Side view of chicken breast piece used for depth of penetration measurement B. Overhead view of the 
chicken breast piece C. Maximum intensity projection PAM image of the hairs inside the chicken breast. The hair on 
the left side of the image is close to the surface and the hair on the right side of the image is about 2 mm deep. D. B-
line image along the dashed line in Figure 3.4C. Color bars represents normalized PA amplitude. 
3.3.4. PAM image of human hairs 
PAM image of black human hairs positioned to form multiple branches is depicted in 
Figure 3.5A in order to demonstrate the imaging of branch-shaped targets. The hairs were 
measured to be thinner than 100 µm using a standard caliper. The one-dimensional 
cross-sectional profile of the image along the dashed line is presented in Figure 3.5B. 
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FWHM of profiles range between 80 µm to 180 µm. Hairs with thicker profiles in the image 
were positioned slightly out of focus. The pixel size in Figure 3.5A is 6.7 × 18.5 μm in 
horizontal and vertical directions, respectively. 
 
Figure 3.5 A. PAM image of human hairs. The color bar represents normalized PA amplitude. B. One-dimensional 
cross-sectional profile of the image in (A) along the dashed line 
To further demonstrate the capability of imaging branch-shaped targets lying deep in the 
tissue, crossing black human hairs inserted about 1 mm below the surface of a chicken 
breast were imaged. Figure 3.6A and 3.6B show the side and overhead views of the 
chicken breast piece and Figure 3.6 C shows the PAM image of the hairs. The hairs are 
clearly resolved with ~15 dB SNR. The pixel size in Figure 3.6C is 8.3 × 8.4 μm in the 
horizontal and vertical directions, respectively. 
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Figure 3.6 A. Side view of chicken breast piece with crossing hairs inserted ~1 mm below the breast surface B. 
Overhead view of the chicken breast piece. C. PAM image of the crossing hairs inserted about 1 mm below the 
chicken breast surface 
3.3.5. PAM image of mouse ear ex vivo 
Ex vivo PAM image of a mouse ear and its photograph are presented in Figure 3.7A and 
3.7B, respectively.  Mouse ears were obtained from the University of Connecticut animal 
facility and the institutional oversight was waived. The thin vessels inside the rectangle 
are all resolved in the image, even the vessels that have lost blood during the incision 
and appear less clear in the photograph. The pixel size in Figure 3.7A is 5 × 12.3 μm in 
horizontal and vertical directions, respectively. PAM image of another ex vivo mouse ear 
and its photograph are presented in Figure 3.7C and 3.7D, respectively. As it can be seen 
from the photograph, the ear was imaged from inside rather than outside so that the 
vessels on the left side of the rectangle in Figure 3.7D lay deeper in the tissue. However, 
these vessels, as indicated by solid arrows, are clearly resolved in the image. Moreover, 
the areas where blood is not continuous in the vessel, as indicated by dashed arrows, are 
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distinguished with details. The pixel size in Figure 3.7C is 4.4 × 6.9 μm in horizontal and 
vertical directions, respectively. The SNR for imaging mouse ear ex vivo is ~ 14 dB. 
 
Figure 3.7 A and C. PAM image of the vasculature on a mouse ear ex vivo. The color bars represent normalized PA 
amplitude.  B and D. Photograph of the mouse ear in (A) and (C), respectively. 
3.3.6. PAM image of porcine ovary ex vivo 
To evaluate the capability of the system for imaging ovarian tissue, a porcine ovary was 
imaged ex vivo. Porcine ovaries were obtained from a local farm and the institutional 
oversight was waived. PAM image of the ex vivo porcine ovary and its photograph are 
presented in Figure 3.8A and 3.8B, respectively. As can be seen, the system is capable 
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of resolving thin vessel branches that are positioned under the tissue surface and are not 
apparent in the photograph. The pixel size in Figure 3.8A is 2.9 × 10.1 μm in horizontal 
and vertical directions, respectively. The SNR for imaging porcine ovary ex vivo is ~ 18 
dB.  
 
Figure 3.8 A. PAM image of the vasculature on a porcine ovary. The color bar represents normalized PA amplitude. 
B. Photograph of the porcine ovary 
FWHM of the vessel branches indicated by the arrows in Figure 3.8A are 50-65 μm. 
Considering the ability to resolve such vessels on the porcine ovary and the ~21 μm 
resolution, the system shows potential sensitivity to arterioles, venules, angiogenic 
sprouting clusters, and micro-vessel clusters, which are present in tumor angiogenesis 
[6,8,31,52–56]. Also most of the vasculature in the sample PAM images of normal and 
malignant ovarian tissue presented in Ref. [27], where the authors use feature extraction 
of PAM images to classify normal and malignant ovarian tissues, are of similar or larger 
sizes [27]. The FOV of the presented ovarian tissue PAM image is ~ 1.5mm × 3mm. Such 
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an area can potentially contain part of the vasculature feeding or surrounding a tumor 
cite. Therefore, when combined with feature extraction algorithms to analyze the 
configuration and distribution of the vasculature [27], the proposed low-cost and fast laser 
diode based laser scanning photoacoustic microscopy system has the potential of 
imaging and classification of ovarian cancer, providing an important step towards the 
clinical application of PAM for studying ovarian cancer. 
3.4. Discussion 
The proposed PAM system offers significant improvement in the imaging speed 
compared to previously reported low-cost laser diode-based PAM systems [39–43], 
eliminates the need for mechanical scanning of the sample, and has demonstrated the 
potential for imaging and classification of ovarian tissue. Even though laser scanning PAM 
systems utilizing conventional solid-state lasers with comparable or higher speeds  have 
been reported previously [57,58], this is the first implementation of a fast laser scanning 
PAM system using a low-cost and small pulsed laser diode. The PLD used in this paper 
is approximately $540 and the PLD driver is approximately $1350, resulting in a total of 
$1890, which is significantly lower than the cost of conventional photoacoustic light 
sources. The proposed system is therefore one step closer to low-cost, compact, and fast 
PAM devices valuable for clinical use. 
A PAT system using a pulsed laser diode as the excitation source (lateral resolution of 
180 or 380 µm with a 5 MHz or 2.5 MHz transducer, respectively) has been developed 
by other researchers [44]. The cost of the PLD used in the PLD-PAT system is ~ $15k 
[44]. Therefore, given that the system proposed here is much less expansive and yet can 
provide ~21 µm lateral resolution makes it worthwhile to use. Additionally, to obtain a 
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lateral resolution of 21 µm with acoustic resolution PAM, the required frequency of the 
focused ultrasound transducer should be higher than 75 MHz [59]. Such transducers 
(especially focused ones) are not commercially available and are very expensive if 
custom designed. For instance, several examples of acoustic resolution PAM using 
conventional light sources have used a transducer with 50 MHz central frequency and 
70% bandwidth with a lab-made acoustic lens of 0.44 numerical aperture and have 
reported 45 µm lateral resolution [19,20,60,61]. Currently, we are not aware of any 
acoustic resolution PAM systems utilizing low-cost PLDs.  
The theoretical diffraction limited resolution of optical resolution PAM is estimated as 0.5 
λ/NA, where λ is the wavelength and NA is the numerical aperture of the lens. With a 905-
nm wavelength and 0.71 numerical aperture, the diffraction limited resolution is 0.63 µm, 
which is much smaller than the resolution obtained in this setup. In order to reach the 
diffraction limit, the laser light should have a Gaussian profile and it should have a very 
small divergence angle. Using fast/slow axis microlens collimators can improve the beam 
profile, collimation, and consequently the focusing [62]. Also, using beam expanders with 
larger expansion ratios can further decrease the divergence angle and improve the 
collimation and focusing. However, this will increase the beam size and results in more 
light energy loss due to the limited aperture of the scanning mirrors and the focusing lens. 
As a future work, a single, small, two-dimensional microelectromechanical system 
(MEMS) based actuator can be used for laser scanning. Such a scanning mirror can be 
placed after the focusing lens, therefore light will be scanned after the focusing lens rather 
than inside it. As a result, the beam can be further expanded before reaching the lens, 
leading to a smaller divergence angle and a better focusing. It should also be noted that 
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although the focusing lens in this report is a single aspheric lens and introduces less 
aberrations compared to spherical lenses, it is estimated that the resolution degrades 
about 20-30 microns near the edges. Using a specific scanning lens (f-theta, etc.) can 
provide a flatter focal plane for all scanning angles and maintain a fairly similar focal spot 
even near the edges. However, the relative high cost of such lenses, especially with 
numerical apertures as high as 0.71, may affect the low-cost nature of the system. 
Using visible pulsed laser diodes (e.g. 405 nm) would potentially improve the lateral 
resolution. However, NIR light demonstrates better penetration depth in optical resolution 
PAM compared to the visible range [63], which enhances the potential to image vessels 
lying deeper beneath the surface of the ovarian tissue. Moreover, although the absorption 
coefficient of hemoglobin is higher in 405 nm compared to 905 nm, available energies of 
NIR PLDs are higher than those in the visible range [5,43,45]. Light emitting diodes 
(LEDs) have also been reported as photoacoustic light sources [64,65], however due to 
the larger divergence of LED beam compared to laser diodes, it is more challenging to 
obtain low-loss collimation and tight focusing of LED beam [65]. Moreover, PLDs can 
have shorter pulsewidths compared to LEDs, which leads to better axial resolution [65]. 
In order to obtain better axial resolution for high resolution 3D imaging, higher frequency 
ultrasound transducers can be employed. Because in this system PA signals are detected 
in transmission mode and healthy human ovaries are 1.5-2 cm thick and diseased ones 
can have larger sizes [66], we have used a relatively low-frequency ultrasound transducer 
to avoid attenuation of ultrasound waves travelling in the tissue. Considering the current 
SNR level for ovarian tissue imaging, attenuation caused by higher frequency transducers 
in the transmission mode will affect the image quality. Higher frequency transducers can 
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be used in a reflection mode PAM setup that does not require the ultrasound waves to 
pass through the tissue. It has also been shown that application of Wiener deconvolution 
on the axial direction can provide ~1.7 times improvement in the axial resolution [51]. 
Moreover, an unfocused transducer is used in the current system because while light is 
scanned on the sample, the ultrasound transducer is stationary. If a focused transducer 
is used, the detection sensitivity decays rapidly away from the focal spot, hence limiting 
the field of view. Using a focused transducer confocal with the optical excitation, which is 
common in reflection mode PAM systems, can potentially provide about 20 dB increase 
in the detected PA signal level [57,67,68]. It should be noted that considering the limited 
photoacoustic signal level, in order to maintain sufficient SNR without averaging in the 
reflection mode PAM, efficient coupling of the ultrasound signal to the transducer is 
necessary. Due to the properties of the PLD, a high numerical aperture lens (1-inch 
diameter, 17.5 mm focal length, 0.71 NA) is required to reach the desired resolution in 
the current setup. In the reflection mode laser scanning PAM systems, either the 
transducer is placed confocal with the optical focus and both light and acoustic wave are 
steered by the mirror [57], or the transducer is tilted with respect to the sample [58]. In 
both forms, low numerical aperture lenses (NA ~ 0.1, focal length 50 mm [57] or 60 mm 
[58]) are used so that either there is enough space for the mirror and beam combining 
components between the lens and the sample [57] or the transducer has a small degree 
with respect to the sample (30 mm away, 15 degrees tilted [58]). Therefore, achieving 
acceptable resolution and efficient ultrasound signal coupling is a challenge that should 
be addressed in future reflection mode laser scanning laser diode PAM systems. 
Improving the beam profile and collimation will allow achieving acceptable lateral 
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resolution with lower numerical aperture lenses, hence paving the way for the reflection 
mode configuration. 
The light energy directly from the PLD (without the optical system) was measured to be 
approximately 16 µJ and the energy delivered to the tissue was measured to be 
approximately 13 µJ. Assuming the focal spot to be 0.5-2 mm below the surface of the 
sample, the maximum surface optical fluence is estimated to be between 1.6-0.1 mJ/cm2, 
which is far below the maximum permissible exposure (MPE) at this wavelength 
according to the American National Standards Institute (ANSI) safety standard [69].  
Imaging and classification of normal and malignant human ovaries using the proposed 
system is a future task. The imaging speed can also be further increased. The maximum 
repetition rate of this PLD is governed by its absolute maximum duty cycle of 0.1%. 
Therefore, at 50 ns or lower pulsewidths the repetition rate can be increased up to 20 
KHz. Considering that no averaging is required in this system, using an improved data 
acquisition scheme and up to 20 KHz repetition rate of the PLD, the imaging speed can 
be significantly increased. A laser scanning laser diode-based PAM system using a 
MEMS-based two-dimensional actuator with improved imaging speed is currently under 
development to obtain better image quality and imaging speed and move towards a 
reflection-mode setup.  
Furthermore, development and application of photoacoustic contrast agents with 
absorption peaks near 905 nm can enhance the SNR and image quality of this system 
[70–74]. Studying skin and cervical cancer can be other possible applications of a laser 
scanning laser diode based PAM system [18–20,26]. With further developments, 
endoscopic laser diode-based photoacoustic microscopy systems have great potential to 
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provide angiogenesis distribution of ovarian surface during minimally invasive surgery 
which can guide surgeons to reduce unnecessary surgeries [27]. Such systems also have 
great potentials for diagnosis of colorectal [23–25], pancreatic [25], and esophageal [75] 
cancer.  
3.5.  Summary 
A low-cost and fast laser scanning laser diode based photoacoustic microscopy system 
is presented.  The lateral resolution is approximately 21 µm. PAM images of human hairs, 
ex vivo mouse ear, and ex vivo porcine ovary have been presented. The imaging speed 
is significantly higher than previously reported laser diode-based PAM systems and the 
need for mechanical scanning is eliminated.  
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4. In vivo photoacoustic tumor tomography using a quinoline-annulated 
porphyrin as NIR molecular contrast agent 
4.1. Introduction 
The development of new—or the refinement of existing—imaging techniques of 
biological processes and tissue is arguably one of the leading driving forces in 
contemporary biomedical chemistry [1–6]. Photoacoustic imaging (PAI) is a rapid 
and non-invasive imaging modality that combines optical and ultrasound imaging 
[7–9]. Photoacoustic signals are optically generated and ultrasonically detected. It 
thus can take advantage of the optical window of tissue and provides the deep 
probing depth (multiple cm) and spatial resolution (sub-mm) of ultrasound. 
PAI is the consequence of a number of physical effects [9]. The absorption of a 
light pulse by a chromophore causes it to enter an excited state. Good PAI 
chromophores relax rapidly primarily along non-radiative pathways, causing a 
transient rise in temperature (in the mK regime) around the closest vicinity of the 
absorbing dye, leading to a localized thermal-elastic expansion. Thus, if the light 
source is a pulsed laser with a short pulse length, light absorption generates a 
wideband ultrasonic wave. This signal can be acquired with standard ultrasonic 
transducers known from traditional ultrasound imaging. Furthermore, using wave-
lengths within the optical window of tissue (~700-1100 nm; the wavelength of 
maximum penetration of breast tissue is ~725 nm; whole blood has an absorption 
minimum at ~710 nm) [10,11], dyes many centimeters deep within tissue can be 
probed. If such a NIR laser beam is scanned across an object, the photoacoustic 
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data can be used to reconstruct 2D or 3D photoacoustic maps. The laser light 
energy used for in vivo imaging experiments is generally well below the standard 
thresholds above which tissue damages can be expected. Variants of PAI are 
photoacoustic tomography (PAT) [7] for large-scale imaging and photoacoustic 
microscopy (PAM) [12] for small scale, high-resolution image generation. 
Endogenous chromophores, primarily hemoglobin, can be used as PAI dyes [13]. 
This allowed for the imaging of the blood content of the vascular network in rodent 
brains [12] or cancer in breast [14] and ovary tissues [15,16], the mapping of 
mesoscopic biological objects, or whole animals [7]. However, particularly cancers 
in their early stages, cannot be detected by their intrinsic vascular contrast. 
Therefore, the use of exogenous contrast agents is required to achieve a suitable 
signal to noise ratio and to allow the PAI of deeply-seated organs or lesions [13]. 
A number of nano- or micro-scale agents have been introduced as PAI or 
multimodal contrast agents in recent years, with some showing good in vivo 
imaging results [17–22]. Among them are metal-based nanoparticles, combined 
with and without organic dyes, and nanotubes. However, the use of nanoparticles 
is not without problems with respect to biodistribution, toxicity, or homogeneity [23–
25]. Alternative approaches have been the use of molecular dyes assembled into 
vesicles, most prominent among them porphysomes made from chlorins or 
bacteriochlorins, such as pyropheophyrin derivative 1 [18,26], microbubbles 
[19,20], or nanodroplets [21]. Also developed were photoacoustic probes that are 
generated in tissue [27,28]. Conspicuously rare in the contemporary literature are 
small molecular contrast agents designed for PAI [13]. One example is 2, shown 
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to be a suitable contrast agent for imaging dissolved oxygen using photoacoustic 
lifetime imaging [29]. One of the oldest and best studied PAI contrast agents is the 
FDA-approved ocular angiographic dye indocyanine green (ICG, 3), and related 
derivatives [30,31]. ICG possesses NIR absorption (λmax ~ 800 nm) properties but 
is otherwise far from ideal. For example, ICG is, albeit weakly fluorescent. Thus, a 
portion of the absorbed light is not translated into a photoacoustic signal, 
diminishing its effectiveness as a PAI contrast agent. ICG is confined to the 
vasculature space and it clears rapidly (t1/2 < 4 min) [32,33], complicating longi-
tudinal in vivo studies. Irrespective of these shortcomings, the broad utilization of 
ICG suggests its use as a benchmark dye. The absence of the development of 
many molecular contrast agents highlights the fact that reliable structure-function 
relationships that might guide the rational development of photoacoustic dyes 
suitable for their use in biological contexts has not been derived. 
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The synthesis of meso-tetraphenylporphyrin-derived quinoline-annulated 
porphyrins, such as 4a or 5a [34–36] were recently reported. As a consequence of 
the extended π-conjugation and their annulation-induced non-planarity of the 
porphyrinic chromophore, the photophysical properties of quinoline-annulated 
porphyrins are significantly altered when compared to those of the parent 
porphyrin. While regular porphyrins generally do not absorb much past 650 nm, 
quinoline-annulated porphyrins possess unusually red-shifted λmax bands in the 
750 nm range. It was also shown that the bis-annulated systems and quinoline-
annulated chlorins (in which another pyrrole was modified by a non-pyrrole 
heterocycle) are accessible by step-wise conversion of 5a, further manipulating the 
optical properties of this family of porphyrinoids [34–36]. Complementary 
syntheses of some of these derivatives and related chromophores are also known 
[37,38]. 
Crucially, quinoline-annulated porphyrins 4a and 5a were shown to be primarily 
relaxing rapidly non-radiatively, making them very good photoacoustic dyes [31]. 
We demonstrated a ~2.5-fold PAI contrast enhancement for 4a over pure blood or 
ICG in phantom tissue experiments [31]. The realization of the combination of a 
NIR-absorbing chromophore undergoing primarily rapid non-radiating relaxation 
pathways is difficult, as the direct comparison of the photoacoustic signal 
generation efficiency of a number of NIR dyes absorbing in the same wavelength 
range has shown. Despite this promise for 4a or 5a as PAI contrast agents, 
however, their insolubility in aqueous solutions (in the absence of a formulation 
vehicle like Cremophore EL®) prevented their in vivo assessment. 
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We report here firstly the development of a quinoline-annulated porphyrin-based 
single-molecule, serum-soluble PAI contrast agent and the evaluation of its efficacy 
as an in vivo PAI contrast agent for the detection of implanted tumors in a mouse 
model. A multi-fold contrast enhancement when compared to ICG was found, a 
finding that could be traced to its photophysical properties. Its nontoxicity and renal 
clearance rates will be demonstrated. We also prepared a water-soluble quinoline-
annulated derivative of the quinoline annulated porphyrin carrying a small 
fluorescent tag to facilitate the biodistribution studies of this intrinsically non-
fluorescent chromophore. Alas, it was not fluorescent enough to be of utility. 
Nonetheless, the experiment demonstrated a facile and general conjugation 
strategy for these chromophores. 
 
4.2. Synthesis of a freely water-soluble quinoline-annulated porphyrin 
A number of strategies were established to render meso-arylporphyrins water-
soluble [39–44]. Among them are their functionalization with anionic (carboxylate, 
sulfonate, phosphonate) or cationic (pyridinium) groups or their decoration with 
(multiple) polyethylene glycol (PEG) chains. We chose the PEG-strategy for the 
charge neutrality of the final products and previous reports indicating their 
suitability for tumor targeting [43,45]. We found that quinoline-annulated porphyrin 
4a is chemically stable under the classic acidic methoxy deprotection conditions 
(BBr3) but not to, for example, classic basic saponification reaction conditions 
(NaOH, THF). We thus chose the phenol-protected meso-tetrakis(p-
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methoxyphenyl)porphyrin 6b as the basis for the formation of the quinoline-annu-
lated porphyrin chromophore [34], with the intent to deprotect and PEG-ylate the 
phenolic oxygens using standard Williamson alkylation strategies at the last stages 
of the dye synthesis pathways. This strategy was successful as demonstrated by 
the synthesis of the waters-soluble dyes 4d and 4e (Scheme 4.1).
 
Scheme 4.1. Reaction conditions: (i) 1. 1 equiv. OsO4, CHCl3, r.t.; 2. H2S (ii) 4 equiv. DMP, CH2Cl2, r.t. (iii) 100 
equiv. NH2OH·HCl, pyridine, N2 atmosphere, r.t. (iv) DDQ, CH2Cl2, r.t. (v) pyridine, Δ (vi) 1. BBr3, CH2Cl2 (vii) 
Me(OCH2CH2)nOMs, Cs2CO3, DMF, 90 °C.
p-Methoxy-derivatized quinoline-annulated porphyrin 4b was synthesized from 
meso-tetrakis(p-methoxyphenyl)porphyrin 6b using the dihydroxylation  
oxidation  oximation  annulation route established earlier for this chromophore 
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class [34]; all intermediates showed the expected spectroscopic and analytical 
properties [46]. However, some notable deviations from the established protocols 
were implemented. The oxidation of diolchlorin 7 required the use of Dess-Martin 
Periodinane (DMP) for its smooth conversion to the corresponding 2,3-dioxochlorin 
8 [47]. The generally used oxidant DDQ failed to produce this dione [48]; instead 
dehydration to the corresponding enol was observed (the reaction was not further 
investigated). Oxime 9 formed smoothly; its treatment with p-TSA under forcing 
conditions (toluene, reflux) produced the quinoline annulated porphyrin 4b in 
acceptable yields, but this product was contaminated with the corresponding 
N-oxide 5b. Because their separation was tedious, we treated oxime 9 with DDQ, 
thus forming N-oxide 5b as the exclusive product in near-quantitative yields. We 
attribute the electron-rich nature of the p-OMe-substituted oxime to the facile 
annulation and oxidation. N-Oxide 5b could be readily reduced to quinoline 
annulated porphyrin 4b heating to reflux in pyridine. Similarly readily losses of the 
N-oxide were observed previously [34]. Quinoline-annulated porphyrin N-oxide 5b 
was also susceptible to a BBr3-mediated deprotection of the methoxy groups and 
concomitant reduction of the N-oxide, without any noticeable degradation of the 
macrocycle, generating the phenolic quinoline-annulated porphyrin 4c in five linear 
steps from porphyrin 6b. 
Phenol-derivatized quinoline-annulated porphyrin 4c could be PEG-ylated with a 
methoxy-capped PEG-mesylate using a short PEG chain (n = 4), forming 4d, as 
well as a longer chain (avg. MW 550, n ~ 12), forming 4e. ESI+ MS and 1H NMR 
spectra of 4d and 4e confirmed that all four non-equivalent phenolic OH-groups 
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were PEG-ylated. The mass spectra of 4e reflect the slight chain length 
inhomogeneity of the longer PEG-chain [46]. Because of the homogeneity of the 
shorter PEG derivative, we used this derivative for the determination of the 
photophysical properties of the water-soluble quinoline-annulated porphyrins. 
Further details about the synthesis steps, materials, and instrumentations are 
provided in section 4.6.  
4.3. Methods 
4.3.1. Co-registered pulse-echo-photoacoustic tomography 
The details to the 64 channel co-registered ultrasound pulse echo-photoacoustic 
tomography (PE-PAT) system is described elsewhere [49]. Briefly, the system 
utilizes a unique field-programmable gate array (FPGA) technology that allows for 
real-time acquisition of ultrasound and photoacoustic signals. The photoacoustic 
signal is generated by a 15 Hz, 12 ns pulse width light of a tunable Ti-Sapphire 
laser (LT-2211, Symphotics TII Corp, Camarillo, CA) pumped by a second 
harmonic Nd:YAG laser (LS-2134, Symphotics TII Corp). Free space illumination 
is used for light delivery. The laser light is expanded by a combination of concave 
and convex lenses and shone on the sample using mirrors. A small portion of the 
beam is separated by a beam splitter (BSN11, Thorlabs) and is focused on a single 
element ultrasound transducer for monitoring the fluctuations in laser energy during 
the experiment [50]. The pulse-echo (PE) ultrasound signal is generated and 
received by the system in synchrony with the laser pulses. The PE and PAT images 
are formed by a beamforming algorithm. The data sampling is performed at 40 
MHz. A 64 channel ultrasound transducer with a center frequency of 3.5 MHz, a 
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bandwidth of 80%, and a sector scan type is utilized for acquiring the co-registered 
PE-PAT images. Ultrasound and PAT images are overlapped to form the co-
registered images. The effects of laser energy fluctuations are compensated for in 
the data analysis. 
The setup was also used for the phantom photoacoustic signal generation 
efficiency evaluation of the dyes, as described previously [31]. 
4.3.2. Animal protocols 
All experiments involving mice were performed as approved by the Institutional 
Animal Care and Use Committee (IACUC) of the University of Connecticut under 
license #A15-047. 
4.3.3. Toxicity test 
100 µL of PBS based solution of 4e with 33.3 mM concentration was injected into 
anesthetized 6 week old BALB/c mice (n = 2). The heart rates of the mice were 
monitored by a pulse oximeter (MouseStat, Kent Scientific) before injection and 
during a 3 h period after injection. 
4.3.4. Tumor model.  
Tumor cell preparation was adopted from the literature [51,52]. Briefly, 4T1 Luc 
cells were cultured at 37 °C with 5% CO2 in a T75 flask (BD Biosciences, Bedford, 
MA); DMEM (Dulbecco's Modified Eagle's medium, Gibco, USA) medium 
supplemented with 10% FBS and 50 U/mL penicillin/streptomycin. After 3 passes, 
the cells were suspended in the DMEM and 1  105 cells were injected 
subcutaneously on top of the right leg of female BALB/c mice (6-8 weeks old, body 
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weight ~20 g). The mice were monitored for approximately two weeks post-
inoculation until the tumor size was between 7-10 mm. 
4.3.5. In vivo PAT of murine tumor.  
Prior to the in vivo imaging, the mice were anaesthetized (1.5 L/min oxygen with 
1.5% isoflurane) and the tumor area depilated. The position of the mouse was 
fixed. Ultrasound gel was applied on the tumor area and a bag of water was placed 
on top of the tumor for acoustic wave coupling. The pulsed laser at 790 nm of the 
PE-PAT setup described above (780 nm for ICG) was shone on the tumor through 
the water bag; surface optical fluence on the tissue was always maintained below 
the maximum permissible exposure according to the ANSI safety standard [53]. 
The transducer position was adjusted by a three dimensional mechanical stage to 
reach a suitable imaging condition. The pre-injection PAT image of the tumor was 
acquired. Then 100 µL of the PBS based solution of the dye 4e (~33.3 mM 
concentration) or ICG was injected via retro-orbital injection [54]. Care was taken 
to avoid any changes in the position of the mouse, transducer, and light beam as 
a result of the injection. The energy of the laser was monitored and the contribution 
of laser energy fluctuation on the PAT signal was compensated for in the data 
analysis [30,50]. The PAT images of the tumor were acquired during the 45 min 
period following injection. The PAT images and the maximum PA signal levels were 
compared before and after the injection. The schematic of the in vivo experiment 
setup is illustrated in Figure 4.1. 
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Figure 4.1. In vivo PAT experiment setup. N: Nd:YAG second harmonic laser, T: tunable Ti:sapphire laser, L1, L2, L3: 
lenses, BS: beam splitter, SE Tr: single element transducer for monitoring laser fluctuations, O: oscilloscope, M: 
mirror, WB: water bag, Tr: transducer, H: heater, NC: nose cone, A: anesthesia compound (1.5 L/min oxygen with 1.5 
% isoflurane), PE-PAT: the co-registered PE-PAT system, PC: computer. 
4.3.6. Ex vivo fluorescent imaging 
100 µL of the fluorescent tagged dye (3 mM in PBS) was injected to three BALB/c 
mice of similar weight and similar tumor size. The mice were sacrificed 15 and 120 
min after the injection. Tumor, liver, kidneys, heart, lung, and spleen were 
harvested, washed twice in PBS, and imaged using an IVIS® Lumina II fluorescent 
imaging system (Caliper Life Sciences, Hopkinton, MA); λexcitation = 465 nm, GFP 
emission filter. 
4.3.7. Photophysical measurements.  
The photophysical measurements were performed as described previously [31]. 
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4.4. Results and discussion 
4.4.1. Photophysical properties and solubility of PEGylated quinoline-
annulated porphyrins 4d and 4e. 
The presence of the four p-methoxy groups in 4b (or the four p-OH groups in its 
deprotected derivative 4c) is reflected in a slight red-shift of its optical spectrum 
(λmax = 762 nm for 4b, λmax = 748 nm for 4c) when compared to the spectrum of 4a 
(λmax = 728 nm), but the overall characteristics of the quinoline-annulated 
porphyrins are not altered (Figure 4.2A) [31]. 
 
Figure 4.2. UV-vis spectra (A: CH2Cl2, B: H2O) of the compounds indicated. 
The shorter PEG derivative 4d is highly soluble in CH2Cl2 as well as alcoholic 
solvents, but is only slightly soluble in pure water. The PEG-ylated quinoline-
annulated porphyrin 4e is freely soluble in alcohols, water, serum, and PBS buffer. 
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As expected, the PEGylated derivatives 4d and 4e possess a λmax value of 764 nm 
in CH2Cl2. Both compounds exhibit some modest degree of solvatochromism. The 
spectrum of 4e in water, for example is slightly blue-shifted and overall broadened 
(Figure 4.2B). 
The dissolution of 100 mg 4e/mL PBS was readily possible, forming a 33.3 mM 
solution. The solubility is therefore at ~ 2 orders of magnitude higher than the 
reported value for ICG in water [55]. The Lambert-Beer law is maintained for 
aqueous concentrations up to 0.03 mM (the upper limit we could measure in a 
1 mm path length cell) but the addition of the surfactant TritonTM X-100 to dilute 
solutions slightly blue-shifts and enhances the Soret band [46], suggesting that 4e 
is somewhat aggregated in aqueous solution. The solutions are stable; no 
significant changes were observed in the UV-vis spectra of the solutions over many 
hours, and with only the onset of minor shifts after two weeks (in the dark at 4 °C). 
The fluorescence quantum yield Φ for 4e in CH2Cl2 as well as H2O were determined 
to be significantly below 0.1%. Transient absorption spectra (in the range from 450 
to 900 nm) for 4e in both solvents with pump-probe delay times from 0 to 15000 ps 
delivered no reliable ISC-quantum yield or S1-lifetime data. Thus, excited time 
lifetimes for 4e are well below 1 ps. Correspondingly, 4e in CH2Cl2, H2O, as well as 
H2O-TritonTM X-100 solutions showed no sign for the generation of singlet oxygen 
(1O2), as measured by the time-resolved NIR luminescence spectra of solutions of 
4e (at O.D. = 0.1 at the excitation λ of 532 nm) at 1270 and 1210 nm. Thus, 
PEGylated quinoline-annulated porphyrin 4e, like its parent compound, absorbs 
strongly within the spectroscopic window of tissue, is non-emissive, not generating 
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1O2, and characterized by at least 3 order of magnitude faster relaxation kinetics 
than meso-tetraphenylporphyrin [31]. These are all excellent properties for a 
photoacoustic imaging agent. 
4.4.2. Ex vivo Photoacoustic Signal Generation of Water-soluble Quinoline-
annulated Porphyrin 4e 
The strength of a photoacoustic (PA) signal generated by an irradiated sample is 
dependent upon the excitation source, absorption coefficient of the sample, 
solvent, the Grüneisen parameter, and the thermal efficiency term that represents 
the efficiency of the photoacoustic signal generation [11]. We previously demon-
strated in tissue phantom studies the 2.5-fold increase of the photoacoustic signal 
resulting from quinoline-annulated porphyrin 4a (dissolved in PBS–1% DMF–1% 
Cremophore EL®) over the signal resulting from blood at identical absorbance 
values [31]. Water-soluble quinoline-annulated porphyrin 4e dissolved in water 
exhibits a similarly excellent performance. In detail, the relative ex vivo 
photoacoustic signal generation efficiency of the dye 4e placed in a translucent 
polyethylene tube submerged in a water bath was compared against that of day-
old rat blood in the same setup and otherwise identical irradiation and detection 
conditions. The concentration of 4e was adjusted so as to possess the identical 
absorbance value of the blood sample at 790 nm, the wavelength of the laser used 
to excite the dye. The co-registered PE-PAT images clearly show that the tube 
filled with 4e generated a 4-fold stronger signal, thus generating a much higher 
contrast image than the blood sample (in water, 1 cm scan depth; Figure 4.3A and 
4.3B). 
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In tissue, light is significantly scattered and absorbed. The fat emulsion Intralipid® 
provides a strongly scattering medium for light [56]. Thus, at 2.5 cm depth, only a 
small fraction of the light energy is delivered to the targets [11]. In fact, at the light 
level used in the experiment, the blood sample could not provide any PA signal 
higher than the noise level (Figure 4.3C), while the tube filled with 4e still delivers 
a well-resolved and high-contrast image (Figure 4.3D), demonstrating its potential 
as a PAI contrast agent. 
 
Figure 4.3. Co-registered PE-PAT images of polyethylene tubes (inner/outer Ø = 0.58/0.96 mm) filled with (A and C) 
one-day-old rat blood and (B and D) with a solution of PEG-ylated quinoline-annulated porphyrin 4e at a 
concentration in which the sample possessed the identical absolute absorbance value at 790 nm as the undiluted 
blood. In each image pair (A-B and C-D) the PAT signal was normalized to the maximum value recorded from the 
tube filled with 4e. Samples immersed in water (A and B, PA signal dynamic range of -12 dB, the threshold is 25% of 
maximum) and Intralipid® (C and D, dynamic range of -15 dB, the threshold is 18% of maximum) at 1 cm (A and B) 
and 2.5 cm (C and D) scan depths, respectively. Vertical image axis is approximately parallel to the tube length and 
horizontal axis represents imaging depth. 
4.4.3. Toxicity of PEGylated quinoline-annulated porphyrin 4e 
Anesthetized 6 week old BALB/c mice were treated with 100 µL of a 33.3 mM PBS 
solution of 4e via retro-orbital injection and their heart rates were monitored for 3 h 
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after injection. No signs of distress of the mice were observed. They also lived for 
several weeks after the injection with normal weight gain, and showed no abnormal 
behavior. The majority of the dye is excreted via the renal pathway within the first 
hour after injection (see also below). These are all promising preliminary 
indications for the absence of any acute toxicity of the PEG-ylated quinoline-
annulated porphyrin 4e. 
4.4.4. The use of quinoline-annulated porphyrin 4e as an in vivo PAI contrast 
agent 
As a result of the solubility, apparent non-toxicity, and high PA signal generation 
efficiency of the PEG-ylated dye 4e, we tested the efficacy of this dye as an in vivo 
PAT contrast agent in a mouse model. The dye 4e (100 µL of a 33.3 mM of 4e in 
PBS) was administered via retro-orbital injection to anesthetized BALB/c mice with 
tumors (7-10 mm) implanted in their flanks [54], and the PE and co-registered PE-
PAT images were recorded, beginning 1 min after injection (Figure 4.4A-B). The 
PE image shows the outline of the tumor and serves as backdrop to the PA image. 
Before injection, only few pixels of the PA image possess high enough signal 
strength to exceed a threshold value (25% of the maximum PA signal after 
injection). Proximately after injection (1 min), an ~ 4-fold increase in the PAT signal 
strengths originating from the tumor site are recorded. The enhancement of the PA 
signal was monitored for 45 min after injection, seeing a gradual loss of the signal 
strength, but even after 45 min, an at least 2-fold PA signal enhancement was still 
achieved (Figure 4.5). In comparison, injection of 100 µL ICG solution of identical 
absorbance at 780 nm as 4e at 790 nm ([ICG] = 1.33 mM) provided a significantly 
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lower PA signal strength enhancement (~1.6-fold) (Figures 3C-D), with no 
enhancement after less than 30 min (Figure 4.5). Thus, the rate of which dye 4e is 
excreted (via renal pathways, see below) is significantly slower than the well-known 
rapid excretion rate of ICG [32,33]. The effect of PEG-ylation on increasing the 
blood circulation time of small molecules has also been described [45,57]. The p-
values in a student t-test between the results obtained for the dye and ICG are less 
than 0.005 for all instances, indicating statistical significance. 
 
Figure 4.4. Co-registered PE-PAT images before injection of the contrast agent (A) and ICG (C) and after the 
systemic injection of 4e (B) and ICG (D). In each image pair (A-B and C-D) the PAT signals were normalized to the 
same maximum value recorded after the injection; a similar dynamic range of -12 dB is applied to all images (the 
threshold is 25% of the maximum value). The vertical axis is approximately parallel to the surface of the mouse body 
and the horizontal axis represents the depth inside the body. 
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Figure 4.5. Time-dependence of the relative enhancement of the PAT max value following the injection of 100 µL of 
the dye 4e (~33.3 mM, λexcitation = 790 nm) and ICG (1.33 mM, λexcitation = 780 nm) at identical absorbance value. 
4.4.5. Renal filtration of quinoline-annulated porphyrin 4e 
An early indication for the biodistribution of dye 4e was the observation of the 
change in the color of the urine excreted immediately after the imaging experiments 
(after ~45 min) to the color of the dye (Figure 4.6). This indicates a very efficient 
renal filtration of the dye. UV-vis (and HPLC-MS [46]) of the urine were able to 
show that imaging agent 4e was excreted in an unaltered form. 
 
Figure 4.6. A. PEG-ylated quinoline-annulated dye 4e dissolved in PBS (~33.3 mM) in a microcuvette. B. Mouse urine 
collected after ~45 min after injection of 4e in a capillary tube. C. UV-vis spectrum (CH2Cl2) of mouse (diluted) urine 
obtained after injection of 4e. 
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4.4.6. Fluorescent-tagging of quinoline-annulated porphyrin 4e 
Quinoline-annulated porphyrin 4e is non-fluorescent. However, the recording of 
fluorescent images of organs or the measurement of the dye-specific fluorescence 
of organ or biofluid extracts are convenient methodologies to track the 
biodistribution of any fluorophore. Thus, we opted to prepare a fluorophore-tagged 
derivative of quinoline-annulated porphyrin 4e. Recognizing that FRET processes 
might be particularly efficient of quenching the fluorescence of the tag at the 
absorption maxima of quinoline-annulated porphyrins, we looked for fluorophores 
that emit in an area of relative minor absorption of these chromophores 
(Figure 4.2). BODIPYs are well-established low molecular weight fluorophores of 
high brightness and multiple options to adjust their optical spectra. Furthermore, a 
recent report describing the reaction of meso-mercapto-BODIPY derivative 10 with 
phenols to generate the meso-phenoxy-BODIPY derivative 11 (Scheme 4.2) [58] 
seemed most suitable for our task of tagging a tetra-phenol-derived quinoline-
annulated porphyrin. Moreover, the emission λmax of 495 nm for 11 lies within the 
target range, and the attachment of the fluorophore at the most distal position to 
the porphyrinic chromophore would also reduce the chances for any FRET. 
 
Scheme 4.2. Reaction Conditions: (i) Na2CO3, MeCN, 55 °C. 
Thus, we chose to attach a single BODIPY moiety to one of the four phenolic 
oxygens of tetraol 4c, followed by exhaustive PEG-ylation of the remaining three 
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phenol functionalities (Scheme 4.3). In anticipation of the copper-catalyzed 
reaction chosen for the conjugation of the fluorescent tag to quinoline-annulated 
porphyrin 4c, its central cavity was protected by insertion of zinc(II). A Cu(I) 
thiophene-carboxylate (CuTC)-mediated reaction of meso-mercapto-BODIPY 10 
[58], followed by an acid-mediated removal of the zinc protecting group using a 
mineral acid wash, generated quinoline-annulated porphyrin 4f in which one of the 
phenolic oxygens was derivatized with the BODIPY group, while the other three 
groups remained unmodified (as per ESI+ MS). The lack of regioselectivity of this 
reaction is reflected in the complex 1H NMR spectrum of this compound [46]. 
 
Scheme 4.3. Reaction conditions: (i) 1. Zn(OAc)2·2H2O, CH2Cl2/MeOH, Δ; 2. 1 equiv 10, Na2CO3, CuTC, CH3CN, 
50 °C; 3. aq. HCl. (ii) Me(OCH2CH2)12OMs, Cs2CO3, DMF, 90 °C 
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The three phenolic oxygens of 4f were then PEG-ylated using the long PEG 
mesylate as described above. Product 4g, a deep yellow oil, shows the expected 
composition (as per MALDI MS). It is freely water-soluble. The presence of the 
BODIPY is seen in the (complex) 1H NMR spectrum of 4g by the observation of 
the diagnostic peaks for the α- and β-protons of the BODIPY moiety (at δ = 6.5-7.0 
ppm). Its 19F NMR spectrum indicates the presence of fluorine atoms at δ = -146.4 
to -146.6 ppm, the typical range for BODIPY fluorine atoms. 
The UV-vis spectrum of non-PEGylated derivative 4f is derived from a linear 
addition of the spectrum of tetraol 4c and BODIPY 11 (Figure 4.7A), with only some 
minor shifts and broadening likely derived from the presence of four regioisomers. 
Upon PEGylation of 4f, the UV-vis spectrum is further broadened, with retention of 
the overall character of the quinoline-annulated derivatives (Figure 4.7B). 
When dyad 4g is excited at the λmax value of the BODIPY moiety (at 441 nm), the 
molecule emits at 485 nm, this emission can be attributed to the BODIPY portion 
of 4g [58]. However, the fluorescence yield Φ for 4g is estimated to lie below 0.3%, 
i.e., much lower than the fluorescence yield Φ for 11 [58]. This suggests that some 
FRET (or other quenching) mechanisms are operative in 4g, but that this 
quenching is not efficient enough to entirely switch off the fluorescence of the 
BODIPY moiety. This further questions the possibility whether it might be possible 
to track dyad 4g in tissue using a fluorescence scanner. 
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Figure 4.7. A. UV-vis spectra of 4f (black) and 11 (red) (solid lines), and fluorescence emission (red broken line; 
λexcitation = 441 nm) for phenoxy-BODIPY 11 (all MeOH). B. UV-vis (solid line) and fluorescence emission (broken line; 
λexcitation = 441 nm) spectra of quinoline-annulated porphyrin-BODIPY dyad 4g (MeOH)). 
4.4.7. Biodistribution study of BODIPY-tagged quinoline-annulated porphyrin 
4g 
The biodistribution of the BODIPY-labeled derivative 4g in the tumor and other 
organs was studied by ex vivo fluorescent imaging, following the injection of 4g 
into 4 BALB/c mice as described for 4e. The mice were sacrificed after 15 or 120 
min after injection, the organs extracted, and their radiant efficiency fluorescent 
images recorded (λexc = 465 nm; GFP emission filter). Unfortunately, however, the 
high amount of tissue auto-fluorescence in that wavelength, did not allow the 
recording of high-contrast images. We note, however, that the tumor was yellow 
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stained, suggesting an accumulation of the dye 4g in the tumor. Similarly, the tumor 
was visibly dark brown stained after the injection of 4e (Figure 4.8). 
 
Figure 4.8. A. A mouse tumor without injection. B. A mouse tumor 48 h after injection of 100 µL of a 33 mM solution 
of 4e in PBS, showing the dark brown-stained tumor site. 
4.5. Summary 
In conclusion, we have demonstrated the in vivo efficacy of serum-soluble 
quinoline-annulated porphyrin derivative 4e as a molecular contrast agent for 
photoacoustic tomography. The solubilization of the quinoline-annulated porphyrin 
followed a straight-forward PEGylation strategy, with the lengths of the PEG chains 
determining the solubility of the final product. The product appeared to be low acute 
toxicity, accumulated in the tumor site, and was rapidly excreted in unaltered 
fashion via renal pathways. The general solubilisation strategy is conceivably also 
suitable to other quinoline-annulated porphyrin derivatives. Conjugation of the non-
fluorescent PEGylated quinoline-annulated porphyrin to a fluorophore was also 
demonstrated, but the hopes to utilize this derivative for the tracking of the 
biodistribution of the contrast agent using fluorescence imaging was not fulfilled. 
Nonetheless, the flexible derivatization strategy points the way toward the 
conjugation to other molecules. 
4. In vivo PAT using QA porphyrin as NIR CA 
79 
4.6. Synthesis: Materials and instrumentation 
All solvents (Aldrich, Acros) and reagents MeO-PEG4-OMs (Aldrich) and MeO-
PEG12-OMs (Creative Peg Works), CuTC (Aldrich) were reagent grade, or better, 
and were used as received. meso-Tetrakis(p-methoxyphenyl)-2,3-dihydroxychlorin 
(7) [59], and BODIPYs 10 and 11 were prepared as described previously [58]. 
Analytical (aluminum backed, silica gel 60, 250 µm thickness) and preparative (20 
× 20 cm, glass backed, silica gel 60, 500 µm thickness) TLC plates, and the flash 
column silica gel (standard grade, 60 Å, 32-63 µm) used were provided by Sorbent 
Technologies, Atlanta, GA.  
1H and 13C NMR spectra were recorded on Bruker Avance II 400 and Bruker 
Avance I 500 instruments in the solvents indicated, and were referenced to residual 
solvent peaks. High and low resolution ESI mass spectra were provided by the 
Mass Spectrometry Facilities at the Department of Chemistry, University of 
Connecticut. MALDI MS Spectra were provided by the Mass Spectrometry & 
Proteomics Facility at the University of Notre Dame. UV-vis and fluorescence 
spectra were recorded on Cary 50 and Cary Eclipse photospectrometers, Varian 
Inc, respectively, and IR spectra on a Bruker Alpha-P FT-IR spectrometer using a 
diamond ATR unit. 
 
meso-Tetrakis(p-methoxyphenyl)-2,3-dioxoporphyrin (8). Diol 7 (270 mg, 3.51 
× 10-4 mol) was dissolved in CH2Cl2 (60.0 mL) in a round-bottom flask equipped 
with a magnetic stir bar. To the stirring solution was added Dess-Martin 
periodinane (590 mg, 1.39 × 10-3 mol, 4 equiv) in portions at ambient temperature. 
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When the starting material was consumed (reaction control by UV-vis and TLC), 
the reaction was quenched by addition of a sat’d aq NaHCO3 solution. The organic 
layer was isolated and washed with H2O (3 × 30 mL). The organic layer was dried 
over anhyd Na2SO4 and evaporated to dryness by rotary evaporation, and the 
residue purified by column chromatography (silica-CH2Cl2) to yield 8 as a dark blue 
powder in yields ranging from 65 to 90% (243 mg): Rf (CH2Cl2-silica) = 0.52; 1H 
NMR (400 MHz, CD2Cl2) δ 8.81 (d, 3J = 4.9 Hz, 1H), 8.65 (d, 3J = 4.9 Hz, 1H), 8.61 
(s, 1H), 8.06 (d, 3J = 8.6 Hz, 2H), 7.84 (d, 3J = 8.6 Hz, 2H), 7.31-7.24 (m, 4H), 4.07 
(two overlapping s, 6H), -1.90 (br s, 1H, exchangeable with D2O); 13C NMR (100 
MHz, CD2Cl2): δ 188.2, 159.9, 159.6, 155.64, 155.62, 155.59, 140.9, 140.2, 138.4, 
135.3, 134.1, 133.8, 133.4, 131.8, 128.4, 128.0, 123.9, 113.4, 112.65, 112.54, 
112.47, 55.5, 55.4 ppm; UV-vis (CH2Cl2) λmax (log ε) 410 (5.26), 477 (4.26) nm; FT-
IR (neat, diamond ATR) 1730 (C=O) cm-1; HR-MS (ESI+, 100% CH3CN, TOF) m/z 
calcd for C48H37N4O6 ([M·H]+) 765.2713, found 765.2726. 
 
meso-Tetrakis(p-methoxyphenyl)-2-hydroxyimino-3-oxoporphyrin (9). Dione 
8 (94 mg, 1.2 × 10-4 mol) was dissolved in pyridine (30.0 mL) in a round bottom 
flask equipped with a magnetic stir bar and N2 inlet. Hydroxylamine hydrochloride 
(NH2OH·HCl, 850 mg, ~100 equiv) was added, and the mixture was stirred for 24 
h at ambient temperature. When the starting material was consumed (reaction 
control by TLC), the reaction mixture was evaporated to dryness by rotary 
evaporation. The residue was taken up in CH2Cl2 and filtered through a glass frit 
(M). The volume of the filtrate was reduced and submitted to column 
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chromatography (silica-CH2Cl2/1% MeOH) to afford the olive-green product 9 in 
60% yield, (58 mg): Rf (silica-CH2Cl2/1% MeOH) = 0.65; 1H NMR (400 MHz, 
CD2Cl2) δ 15.78 (br s, 1H, exchangeable with D2O), 8.81 (d, 3J = 5.7 Hz, 2H), 8.62 
(t, 3J = 8.4 Hz, 4H), 8.03 (dd, 3J = 8.4, 4J = 2.0 Hz, 4H), 7.85 (dd, 3J = 8.4 Hz, 4H), 
7.27-7.19 (m, 8H), 4.05 (s, 12H), -2.23 (br s, 1H exchangeable with D2O), -2.36 (br 
s, 1H exchangeable with D2O) ppm; 13C NMR (100 MHz, CD2Cl2) δ 188.2, 159.82, 
159.75, 159.6, 156.4, 154.9, 151.9, 145.4, 141.1, 139.8, 138.9, 138.80, 137.98, 
135.4, 134.4, 133.6, 133.50, 133.47, 132.1, 128.6, 128.4, 127.63, 127.57, 123.8, 
121.8, 115.8, 113.0, 112.7, 112.4, 112.2, 55.5, 55.42, 55.39, 53.8 ppm; UV-vis 
(CH2Cl2) λmax (log ε) 410 (5.44), 465 (sh), 613 (4.04), 670 (sh) nm; FT-IR (neat, 
diamond ATR): 1732 (C=O) cm-1; HR-MS (ESI+, 100% CH3CN, TOF) m/z calcd for 
C48H38N5O6 ([M·H]+) 780.2822, found 780.2801. 
 
meso-Tris(p-methoxyphenyl)(p-methoxy)quinoline-annulated porphyrin N-
Oxide (5b). Oxime 9 (14.7 mg, 1.88 × 10-5 mol) was dissolved in CH2Cl2 (10.0 mL) 
in a round bottom flask equipped with a magnetic stir bar. To the stirring solution 
was added 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ, 9 mg, 2 equiv) and 
the mixture was stirred at ambient temperature for 0.5 h. When the starting material 
was consumed (reaction control by UV-vis and TLC), the reaction mixture was 
filtered through a plug of silica gel. The filtrate was washed with water (2 × 10 mL), 
dried over anhyd Na2SO4, and evaporated to dryness by rotary evaporation. The 
resulting residue was purified by column chromatography (silica-CH2Cl2/1% 
MeOH) to afford the brown product 5b in 97% yield (14 mg): Rf (silica-CH2Cl2/2% 
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MeOH) = 0.22; 1H NMR (400 MHz, CDCl3) δ 8.54 (d, 3J = 4.2 Hz, 1H), 8.41 (d, 3J 
= 4.9 Hz, 1H), 8.35-8.28 (m, 3H), 8.19 (dd, 3J = 4.3 Hz, 2H), 8.03 (d, 3J = 2.0 Hz, 
1H), 7.86-7.80 (m, 4H), 7.68-7.65 (m, 2H), 7.23-7.20 (m, 4H), 7.16-7.10 (m, 3H), 
4.08-4.04 (m, 10H), 3.89 (s, 3H), -0.32 (br s, 2H, exchangeable with D2O) ppm; 13C 
NMR (100 MHz, CDCl3) δ 185.0, 159.9, 159.6, 159.3, 159.0, 155.9, 153.6, 145.9, 
143.7, 143.5, 141.6, 138.2, 135.6, 135.5, 135.2, 134.9, 134.3, 133.7, 133.4, 133.3, 
133.10, 132.98, 132.94, 131.0, 129.3, 127.7, 127.4, 127.3, 124.5, 123.8, 122.7, 
120.9, 113.2, 113.1, 112.6, 112.5, 102.1, 101.9, 56.0, 55.6, 55.54, 55.47 ppm; UV-
vis (CH2Cl2) λmax (log ε) 422 (5.02), 504 (4.27), 543 (4.16), 751 (4.09) nm; FT-IR 
(neat, diamond ATR): 1686 (C=O) cm-1; HR-MS (ESI+, 100% CH3CN, TOF) m/z 
calcd for C48H36N5O6 ([M·H]+), 778.2666, found 778.2693. 
 
meso-Tris(p-methoxyphenyl)(p-methoxy)quinoline-annulated porphyrin 
(4b). Quinoline N-oxide 5b (23.7 mg, 3.05 × 10-5 mol) was dissolved in pyridine 
(25.0 mL) and heated to reflux for 48 h. When the starting material was consumed 
(reaction control by TLC and UV-vis), the solvent was evaporated and the 
remaining residue was purified by preparative TLC (silica-CH2Cl2/2% MeOH) and 
solvent exchanged from CH2Cl2 to MeOH to afford the brown powder 4b in 44% 
yield (10 mg): Rf (silica-CH2Cl2/2% MeOH) = 0.54; 1H NMR (400 MHz, CD2Cl2): δ 
8.97 (two overlapping d, 3J = 7.5 Hz, 2H), 8.37 (dd, 3J = 7.9, 4J = 4.9 Hz, 2H), 8.22 
(d, 3J = 4.6 Hz, 1H), 8.16 (d, 3J = 4.4 Hz, 2H), 8.00-7.97 (m, 3H), 7.89 (d, 3J = 8.5 
Hz, 2H), 7.73 (d, 3J = 8.4 Hz, 2H), 7.54 (dd, 3J = 9.1, 4J = 2.7 Hz, 1H), 7.28 (d, 3J 
= 8.5 Hz, 2H), 7.22 (dt, 3J = 5.3, 4J = 3.3 Hz, 4H), 4.09 (s, 3H), 4.06 (two overlapping 
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singlets, 6H), 4.03 (s, 3H), 1.07 (s, 2H, exchangeable with D2O); 13C NMR (100 
MHz, CD2Cl2): δ 202.2, 180.4, 160.2, 159.8, 159.4, 159.0, 148.96, 148.85, 148.29, 
148.21, 146.8, 146.56, 146.54, 145.7, 135.5, 134.7, 134.3, 133.5, 133.2, 132.9, 
132.3, 131.0, 129.9, 127.5, 127.2, 122.9, 120.5, 113.0, 112.9, 112.8, 112.7, 112.6, 
112.3, 110.0, 55.8, 55.6, 55.5, 55.4 ppm; UV-vis (CH2Cl2) λmax (log ε) 418 (5.0), 
490 (4.23), 529 (4.23), 701 (sh), 762 (4.12) nm; FT-IR (neat, diamond ATR): 1716 
(C=O) cm-1; HR-MS (ESI+, 100% CH3CN, TOF) m/z calcd for C48H36N5O5 ([M·H]+) 
762.2711, found 762.2738. 
 
meso-Tris(p-hydroxyphenyl)(p-hydroxy)quinoline-annulated porphyrin (4c). 
Quinoline N-oxide 5b (26 mg, 3.3 × 10-5 mol) was dissolved in dry CH2Cl2 (5.5 mL) 
in a round bottom flask equipped with a magnetic stir bar and N2 inlet. A 1.0 M 
solution of BBr3 in CH2Cl2 (1.35 mL, ~40 equiv) was added drop-wise to the flask 
and the reaction mixture was stirred for 24-48 hours. When the starting material 
was consumed (reaction control by TLC), the excess BBr3 was quenched by the 
careful addition of the reaction mixture to distilled water (10 mL). The resulting 
mixture was extracted with EtOAc (3 × 20 mL), washed with sat’d sodium 
bicarbonate solution and water (2 × 20 mL). The organic layer was then dried over 
anhydrous Na2SO4. The resulting residue was adsorbed onto silica gel and dry-
loaded onto a silica gel column and purified by chromatography (silica-CH2Cl2/10% 
MeOH) to afford 4c in 65% yield (18 mg): Rf (silica-CH2Cl2/10% MeOH) = 0.45; 1H 
NMR (400 MHz, DMSO-d6): δ 10.37 (s, 1H, exchangeable with D2O), 10.09 (s, 1H, 
exchangeable with D2O), 9.97 (s, 1H, exchangeable with D2O), 9.71 (s, 1H, 
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exchangeable with D2O), 8.81 (s, 1H), 8.61 (s, 1H), 8.34 (s, 1H), 8.20 (s, 1H), 8.12 
(d, 3J = 4.4 Hz, 1H), 8.03 (d, 3J = 5.8 Hz, 1H), 7.75 (d, 3J = 7.5, 3H), 7.58 (d, 3J = 
7.8 Hz, 2H), 7.34 (d, 3J = 3.9 Hz, 1H), 7.16 (d, 3J = 7.9 Hz, 2H), 7.11 (d, 3J = 8.2 
Hz, 2H), 7.04 (d, 3J = 8.4 Hz, 2H) ppm; 13C NMR (100 MHz, DMSO-d6): δ 194.6, 
158.6, 158.1, 157.5, 157.4, 150.51, 150.49, 150.47, 146.12, 146.10, 142.03, 
141.96, 138.92, 138.89, 136.1, 135.8, 135.43, 135.39, 135.2, 134.7, 134.6, 134.03, 
133.94, 133.4, 132.5, 131.4, 131.1, 130.6, 130.3, 130.10, 130.09, 129.4, 127.86, 
127.83, 127.80, 127.32, 127.30, 127.27, 127.26, 124.59, 124.57, 123.29, 123.26, 
123.20, 123.19, 120.98, 120.96, 120.95, 120.26, 120.25, 115.44, 115.41, 114.95, 
114.92, 114.82, 114.76, 114.68, 111.9, 109.4, 100.0 ppm; UV-vis (MeOH) λmax (log 
ε) 417 (5.15), 487 (sh), 531 (4.31), 748 (4.24) nm; FT-IR (neat, diamond ATR): 
1705 (C=O) cm-1; HR-MS (ESI+, 100% CH3CN, TOF) m/z calcd for C44H28N5O5 
([M·H]+) 706.2090, found 706.2090. 
 
meso-Tris(p-MeOPEG4Ophenyl)(p-MeOPEG4O)quinoline-annulated 
porphyrin (4d). Quinoline-annulated porphyrin 4c (10 mg, 1.4 × 10-5 mol) was 
dissolved in dry DMF (4.0 mL) in a two-neck RBF equipped with a magnetic stir 
bar. MeO-PEG4-OMs (25.0 mg, 8.9 × 10-5 mol, 6 equiv.) and Cs2CO3 (24.2 mg, 7.4 
× 10-5 mol, 5.2 equiv.) were added and the reaction mixture was immersed in a 
preheated oil bath at ~100 °C. After consumption of the starting material after ~3 h 
(reaction control by TLC) the solvent was evaporated and the residue was 
partitioned between EtOAc (10 mL) and H2O (10 mL). The organic layer was 
washed with H2O (3 × 10 mL) and dried over Na2SO4. The brown residue was 
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purified by column chromatography (silicia-CH2Cl2/5% MeOH) to afford the tetra-
PEGylated product 4d as a yellow-brown oil in 56% yield (12 mg): Rf (silica-
CH2Cl2/10% MeOH) = 0.56; 1H NMR (500 MHz, CD2Cl2): δ 9.06-9.04 (m, 2H), 8.40 
(d, 3J = 4.5 Hz, 1H), 8.36 (d, 3J = 5.0 Hz, 1H), 8.23 (d, 3J = 4.5 Hz, 1H), 8.16 (d, 3J 
= 4.5 Hz, 2H), 7.99 (d, 3J = 8.5 Hz, 3H), 7.89 (d, 3J = 8.5 Hz, 2H), 7.71 (d, 3J = 8.5 
Hz, 2H), 7.63 (dd, 3J = 9.1, 4J = 2.5 Hz, 1H), 7.30 (d, 3J = 8.6 Hz, 2H), 7.23 (dd, 3J 
= 8.5, 4J = 1.8 Hz, 4H), 4.44 (t, 3J = 4.5 Hz, 2H), 4.38 (two overlapping t, 3J = 4.7 
Hz, 4H), 4.35 (t, 3J = 4.6 Hz, 2H), 3.99 (dd, 3J = 8.8, 4J = 4.7 Hz, 6H), 3.82-3.77, 
(m, 8H), 3.72-3.57 (m, 34H), 3.55-3.50 (m, 8H), 3.35 (s, 3H), 3.34 (s, 3H), 3.33 (s, 
3H), 3.31 (s, 3H) ppm; UV-vis (CH2Cl2) λmax (log ε) 419 (5.2), 491 (4.5), 531 (4.4), 
764 (4.3) nm; HR-MS (ESI+, 100% CH3CN, TOF) m/z calcd for C80H100N5O21 
([M·H]+), 1466.6905, found 1466.6891. 
 
meso-Tris(p-MeOPEG12Ophenyl)(p-MeOPEG12O)quinoline-annulated 
porphyrin (4e). Prepared from 4c (22 mg, 3.1 × 10-5 mol) in dry DMF (10.0 mL), 
Cs2CO3 (80 mg, 1.6 × 10-4 mol, 5.2 equiv.), and MeO-PEG12-OMs (80 mg, 1.2 × 10-
4 mol, 4 equiv.) as described for the preparation of 4d. Reaction time at 90 °C ~3 h. 
Purified by column chromatography (silica-CH2Cl2/10% MeOH) to afford the tetra-
PEGylated porphyrin 4e as a brown oil in 90-99 % yield (81 mg-89 mg): 1H NMR 
(400 MHz, CD2Cl2): δ 9.04 (s, 1H), 8.38 (two overlapping d, 2H), 8.19 (d, 3H), 7.98 
(t, 3J = 6.6 Hz, 3H), 7.89 (d, 3J = 8.3 Hz, 3H), 7.72 (d, 3J = 8.4 Hz, 2H), 7.63 (d, 3J 
= 8.3 Hz, 1H), 7.31 (d, 3J = 8.5 Hz, 3H), 7.24 (dd, 3J = 8.6, 4J = 2.2 Hz, 4H), 3.34 
(s, 12H) ppm; UV-vis (CH2Cl2) λmax (rel I.) 422 (1.0) 529 (0.20) 763 (0.09) nm; HR-
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MS (ESI+, 100% CH3CN, TOF) cluster of peaks corresponding to addition of four 
PEG groups, see ESI.  
 
[meso-Tris(p-hydroxyphenyl)(p-hydroxy)quinoline-annulated 
porphyrinato]Zinc(II) (4cZn). Quinoline-annulated porphyrin 4c (19 mg, 2.7 × 10-
5 mol) was dissolved in CH2Cl2/10% MeOH (7.0 mL) in a round bottom flask 
equipped with a magnetic stir bar. Zn(OAc)2·2H2O (18 mg, 8.1 x 10-5 mol, 3 equiv.) 
was added and the reaction was gently warmed for 10 min. When the starting 
material was consumed (reaction control by TLC and UV-vis) the solvents were 
evaporated, and the residue was taken up in EtOAc and washed with brine and 
water (3 × 20 mL). The organic layer was dried over anhydrous Na2SO4 and 
evaporated to dryness by rotary evaporation to afford 4cZn as an orange solid in 
near-quantitative yield (21 mg): Rf (silica-CH2Cl2/10% MeOH) = 0.39; 1H NMR (400 
MHz, DMSO-d6): δ 10.23 (s, 1H, exchangeable with D2O), 9.94 (s, 1H, exchange-
able with D2O), 9.85 (s, 1H, exchangeable with D2O), 9.57 (s, 1H, exchangeable 
with D2O), 8.90 (t, 3J = 7.9 Hz, 2H), 8.19 (d, 3J = 4.5 Hz, 1H), 8.05 (d, 3J = 4.6 Hz, 
1H), 7.99 (dd, 3J = 12.1, 4J = 4.4 Hz, 2H), 7.76 (t, 3J = 6.4 Hz, 4H), 7.70 (d, 3J = 8.2 
Hz, 2H), 7.56 (dd, 3J = 9.0, 4J = 2.4 Hz, 1H), 7.47 (d, 3J = 8.2 Hz, 2H), 7.13 (d, 3J 
= 8.3 Hz, 2H), 7.07 (d, 3J = 8.3 Hz, 2H), 7.00 (d, 3J = 8.2 Hz, 2H) ppm; 13C NMR 
(100 MHz CD2Cl2/10% MeOD): δ 195.7, 159.8, 158.1, 157.8, 157.0, 156.6, 152.7, 
152.1, 150.9, 150.5, 150.1, 148.0, 146.3, 143.3, 142.7, 135.6, 135.4, 134.8, 134.6, 
133.8, 133.7, 133.6, 133.52, 133.47, 133.2, 132.0, 131.2, 131.06, 130.13, 130.0, 
126.7, 123.7, 121.0, 115.6, 115.0, 114.7, 114.5, 111.9 ppm; UV-vis (MeOH) λmax 
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(log ε) 420 (5.13), 484 (sh), 518 (sh), 737 (sh), 816 (4.25) nm; FT-IR (neat, diamond 
ATR): ~1750 (C=O) cm-1; HR-MS (ESI+, 100% CH3CN, TOF) m/z calcd for 
C44H26N5O5Zn ([M·H]+) 768.1225, found 768.1222. 
 
p-(BODIPY)-tris-p-(OH)-quinoline-annulated porphyrin, mixture of 
regioisomers (4f). meso-thiomethyl-4,4,-difluoro-4-bora-3a,4a-diaza-s-indacene 
10 (6 mg, 2.7 × 10-5 mol) was dissolved in dry CH3CN (3.0 mL) in a round bottom 
flask equipped with a magnetic stir bar under N2 atmosphere. Tetraol 4cZn (21 mg, 
2.7 × 10-5 mol, 1 equiv) was added and the mixture was stirred for 5 min under N2. 
Copper(I) thiophene-2-carboxylate (CuTC) (5 mg, 2.7 × 10-5 mol, 1 equiv.) and 
Na2CO3 (3 mg, 2.7 × 10-5 mol, 1 equiv.) were added and the reaction mixture was 
immersed in a pre-heated oil bath at 50 °C and stirred [58], After 48 h, a saturated 
aqueous NH4Cl solution was added and the reaction mixture was stirred for several 
hours. The resulting biphasic mixture was extracted with EtOAc (3 × 10 mL), 
washed with H2O (2 × 10 mL), and dried over Na2SO4. The remaining residue was 
purified by column chromatography (silicia-CH2Cl2/10% MeOH) to afford recovered 
4cZn (6 mg) and the mono-BODIPY-tagged product 4f as a series of closely running 
yellow fractions. The combined yellow fractions were dissolved in EtOAc (5.0 mL) 
and treated with 3M HCl (5.0 mL) until the UV-vis spectrum of a neutralized aliquot 
indicated full demetallation. The organic layer was then washed with a sat’d aq. 
NaHCO3 solution and H2O, and was dried over anhyd. Na2SO4 to provide 4f as a 
yellow film in 30% yield (7 mg): Rf (silica-CH2Cl2/10% MeOH) = 0.21; 1H-NMR (500 
MHz, DMSO-d6): δ 10.09-10.07 (m, 1H, exchangeable with D2O), 9.95-9.93 (m, 
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1H, exchangeable with D2O), 9.69-9.64 (m, 1H, exchangeable with D2O), 9.10 (br 
s, 1H), 8.45 (d, 3J = 4.4 Hz, 1H), 8.4-8.37 (m, 1H), 8.18 (d, 3J = 5.2 Hz, 2H), 8.13-
8.10 (m, 2H) 8.08-7.95 (m, 3H), 7.92-7.88 (m, 3H), 7.80-7.77 (m, 4H), 7.60-7.59 
(m, 1H), 7.31 (s, 1H), 7.19 (d, J = 6.0 Hz, 2H), 7.12 (two overlapping d, 3J = 7.8 Hz, 
2H), 7.05-7.03 (m, 2H), 6.81 (d, J = 6.1 Hz, 2H), 6.76-6.72 (m, 1H) ppm; 19F NMR 
(470 MHz, DMSO-d6): δ -142.1 to -142.2, (m) ppm; UV-vis (MeOH) λmax (rel I.) 400 
(1.0), 443 (0.56), 510 (sh), 784 (0.1) nm; Fl (MeOH, λexcitation = 441 nm) λmax 488 
nm; HR-MS (ESI+, 100% CH3CN, TOF) m/z calcd for C53H33BF2N7O5 ([M·H]+) 
896.2599, found 896.2613. 
 
p-(BODIPY)-tris-p-(OPEG12)-quinoline-annulated porphyrin, mixture of 
regioisomers (4g). Prepared according to the procedure for 4e from 4d (10 mg, 
1.1 × 10-5 mol), MeO-PEG550-OMs (22 mg, 3.4 × 10-5 mol, 3 equiv.), 14 mg of 
Cs2CO3 (4.4 × 10-5 mol, 3.9 equiv.) in DMF (2.0 mL) to afford 4g as a yellow oil in 
56% yield (16 mg): 1H NMR (400 MHz, CD2Cl2): δ 9.14 (s, 1H), 8.45 (s, 1H), 8.38 
(d, 3J = 4.6 Hz, 1H), 8.21 (d, 4H), 8.01 (d, 3J = 6.8 Hz, 3H), 7.91 (d, 3J = 7.6 Hz, 
2H), 7.73 (d, 3J = 7.2 Hz, 3H), 7.52 (s, 1H), 7.31 (d, 3J = 8.0 Hz, 4H), 7.25 (d, 3J = 
5.0 Hz, 5H), 7.13-7.11 (m, 2H), 6.82 (d, 3J = 5.7 Hz, 1H), 6.46 (s, 1H) ppm; 19F 
NMR (470 MHz, CD2Cl2): δ -142.1 to -142.2, (m) ppm; UV-vis (CH2Cl2) λmax (rel I.) 
402 (1.0), 473 (sh), 510, (sh), 769 (0.12) nm; Fl (MeOH, λexcitation = 441 nm) λmax 
485 nm; HR-MS (MALDI, 100% DHBA) cluster of peaks corresponding to addition 
of three PEG groups [46] 
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5. A very low-cost, handheld, and multispectral spatial frequency domain 
imaging prototype for ex vivo cancer characterization 
5.1. Introduction 
Optical properties of tissue may vary in healthy and diseased conditions, therefore optical 
imaging modalities capable of providing quantitative maps of absorption and scattering 
properties can assist in characterization of healthy versus diseased tissue [1–3]. Spatial 
frequency domain imaging (SFDI) is a wide-field diffuse optical imaging modality that can 
quantitatively map various optical properties of tissue and has shown potential in 
differentiating benign and malignant tissue in several cancer types including breast and 
ovarian cancer [1–5].  
In SFDI, tissue is illuminated with sinusoidal (or square [6]) spatially modulated light and 
optical properties of the target are reconstructed using the diffusely backscattered light 
collected by a camera [4,5] and single- or multi-wavelength SFDI systems using single or 
multiple spatial frequencies have been demonstrated [2,5,7]. Initial reports of SFDI 
systems utilized general purpose projectors, with built-in digital micro-mirror devices 
(DMMs), to project the spatially sinusoidal pattern, generated in a computer connected to 
the projector, on the tissue [2,4,5,8]. External optical filters were used to select the desired 
wavelength [2,5] and filters could be manually or mechanically switched to use different 
wavelengths. Later versions of SDFI systems utilized LEDs collimated and co-aligned by 
multiple collimating lenses, beam splitters, and dichroic mirrors [1,9]. An external DMM 
controlled by a PC [1], or a printed sinusoidal pattern [9] provides the spatial modulation 
of light that is then projected on the tissue. Such systems generally utilize four LEDs [1]. 
Incorporating and co-aligning larger number of LEDs (for example 9 different 
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wavelengths) in such setups requires many optical components which increases the size, 
cost, and complexity of the system. Albeit, a system incorporating a 6-wavelengths SFDI 
head using custom-made fibers, fiber couplers, and a fiber bundle multiplexer to combine 
all LED lights has been reported previously. However, the light source of this systems is 
both large and the system overall contains many different components that increases its 
cost [10]. Applications of digital light projectors (DLP) as the source for SFDI systems 
have also been demonstrated [11]. In visible DLPs, which are the more common versions, 
RGB LEDs are collimated and co-aligned using collimator lenses, beam splitters, and 
dichroic mirrors and the projection pattern is generated by a DMM [11]. Although common 
(hence, less expensive) DMDs are often sensitive to the visible light, modified DLPs with 
near infrared (NIR) LEDs or laser diodes are also available [12]. However, the custom-
made DLPs are more expensive than the off-the-shelf versions. Moreover, either visible 
or NIR DLPs only use three fixed wavelengths while utilizing a larger number of 
wavelengths from visible to NIR enhances SFDI studies [11,12]. A custom-made spatial 
frequency domain spectroscopy system (analyzing data along a line, rather than forming 
images) incorporating a broadband source into a DLP has also been reported [13] but to 
the best of our knowledge we are not aware of a very low-cost, handheld, and 
multispectral SFDI system with as many as 9 different wavelengths. Here, we report a 
very low-cost, small, 3D-printed, and handheld SFDI prototype incorporating nine different 
LEDs (wavelengths from 660 nm – 950 nm) and all illumination and detection components 
in a handheld probe. 
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5.2. Methods 
5.2.1. SFDI Prototype design 
A schematic representation of the system is shown in Figure 5.1. The illumination portion 
of the prototype consists of a rotational stepper motor (PG20L-D20-HHC0, NMB 
Technologies), 9 LEDs with center frequencies ranging from 660 nm – 950 nm (660 nm, 
740 nm, 770 nm, 810 nm, 830 nm, 850 nm, 890 nm, 935 nm, and 950 nm) placed on a 
custom-designed printed circuit board (PCB), a light diffuser, an achromatic doublet 
collimating lens (Thorlabs, AC254-050-B-ML), a printed sinusoidal pattern (sinusoidal 
pattern is printed on a transparency paper to reduce the cost compared to DMDs or even 
commercially available printed patterns), a linear stepper motor (19541-12-905, Ametek), 
and an achromatic doublet projection lens (Thorlabs, AC254-050-B-ML). On the PCB, 
LEDs are placed on the circumference of a circle with a fixed distance, the rotational 
motor rotates the PCB in order to switch the LED that is positioned on the optical axis of 
the lenses. Light from the LED first passes a beam diffuser to homogenize the beam, it is 
then collimated by the collimating lens. The collimated beam passes the printed pattern 
and is projected on the sample using the projector lens. Design of the illumination portion 
of the probe was guided by Zemax simulations (Zemax, LLC). The printed pattern is 
attached to the linear motor that provides the phase shift between the patterns. Diffuse 
backscattered light is collected by a CMOC camera (EO-0413M-GL, Edmund Optics). 
Two polarizer plates are located at the illumination and detection sides in order to reject 
specular reflection. The illumination area is a circle with diameter of about 13 cm, however 
the detection field of view is about 5 cm × 4 cm approximately 30 cm away from the probe. 
The spatial frequency of illumination is about 1 cm-1 at this distance. Control and 
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synchronization of the parts and detection and data saving are performed in a custom-
made LabVIEW code (National Instrument, Austin, TX, USA) combined with Arduino IDE 
(Arduino, Italy) for controlling the stepper motor drivers and LEDs. The communication 
with the PC is performed through a serial USB port. 
 
Figure 5.1. Schematic representation of the SFDI probe 
All pieces are fixed and aligned in a 3D-printed probe designed in Solidworks (Solidworks, 
Waltham, MA, USA). The illumination section of the probe is 17 cm × 6 cm × 6 cm (length 
× width × height). The camera is held by another piece, designed to fix and align the 
camera with the illumination light and allow for minor modifications if needed. The camera 
holder consists of an adaptor 6 cm × 6 cm × 1 cm that is fixed to the illumination probe, a 
second adaptor 6 cm × 7 cm × 6 cm that is screwed to the first adaptor, and a hollow 
5. SFDI 
103 
cube of 8 cm × 5 cm × 5 cm that holds the camera and is screwed to the second adaptor 
in order to provide a degree of freedom for adjusting the imaging area. The camera holder 
part is completely fixed on top of the illumination part and the entire probe can be held by 
hand or simply fixed on a table. The complete probe is shown in Figure 5.2. Complete 
data acquisition lasts for approximately 2 minutes. 
 
Figure 5.2. The SFDI probe with all illumination and detection components.  
5.2.2. Processing  
The spatial sinusoidal pattern can be represented as: 
In =  I0 sin(2πfxx + 𝜑𝑛)                                                 (5.1) 
where I0 is the source amplitude, fx is the spatial frequency, and φn is the illumination 
phase. Tissue is illuminated with three phase shifted patterns (0, 2π/3, and 4π/3) and the 
DC and AC components (f = 0 and fx) are extracted as: 
MDC =
I1+I2+I3
3
                                                    (5.2) 
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MAC =
√2 
3
[ (I1 − I2)
2 + (I3 − I2)
2 + (I3 − I1)
2]
1
2                            (5.3) 
The DC and AC components of the diffuse reflected light from the target are compared to 
the DC and AC components of a calibrated phantom and the diffuse reflectance is found 
using the calculated diffuse reflectance for the calibrated phantom: 
𝑅𝑑 =
𝑀
𝑀(𝑟𝑒𝑓)
 𝑅𝑑(𝑟𝑒𝑓)                                                 (5.4) 
Here, Rd is the diffuse reflectance of the target and Rd (ref) is the calculated diffuse 
reflectance for the homogenous reference phantom. Therefore two Rd values for DC (f = 
0) and AC (f = fx) components are measured. Finally, a lookup table that relates different 
values of Rd with absorption coefficient and reduced scattering coefficient values is used 
to reconstruct for the absorption coefficient (μa) and reduced scattering coefficient (μ’s) of 
the target at each pixel of the image [5].  
5.2.3. Phantom calibration 
In order to evaluate the SFDI system’s capability in reconstructing the absorption and 
reduced scattering coefficients of turbid media, several liquid phantoms were made with 
Intralipid as the scattering agent and Indian ink as the absorbing agent. Because the SFDI 
probe has several different wavelengths, we calibrated the phantoms using separate 
measurements of scattering and absorption coefficients for each wavelength in a 
collimated transmission setup [14,15]. 
The absorption coefficient of a parent Indian ink solution was measured and the parent 
solution was diluted to different ratios to create different absorption coefficients 
considering the titration equation [16]. It should be noted that in higher wavelengths, 
especially for 935 nm and 950 nm, water has considerable absorption and the absorption 
of water needs to be considered in the calculations [17,18]. Also, it has been shown in 
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the literature that the absorption of Intralipid solution follows the absorption of water [14], 
therefore absorption is mainly governed by the concentration of the Indian ink (and water 
at higher wavelengths).  
The scattering coefficient (μs) of the parent 20% Intralipid solution was measured using 
the collimated transmission setup and the Beer-Lambert law with the assumption that the 
total attenuation coefficient (μt) is the addition of absorption coefficient (μa) and scattering 
coefficient (μs). Given that for the Intralipid solution μs >> μa therefore μt ≈ μs. After careful 
measurements of the scattering coefficient, the determined scattering coefficient was 
close to (within the error margin of) the value reported in the literature [15]. Therefore 
either the measured value or the value from the literature could be used as the μs of the 
undiluted Intralipid solution. The reduced scattering coefficient, which can be measured 
in SFDI is μ’s = μs (1-g), where g is the anisotropy factor and is wavelength dependent 
[15]. We used the value of g available in the literature for Intralipid solution similar to the 
solution used in this study [15]. The Intralipid solution was diluted to different ratios in 
order to form different reduced scattering coefficient values for different phantoms. Optical 
properties of the prepared phantoms were reconstructed by the SFDI probe for different 
wavelengths and were compared to the expected values.  
5.3. Results 
5.3.1. Phantom evaluation 
Figure 5.3 shows an example of the reconstructed and expected values for absorption 
coefficient (A) and reduced scattering coefficient (B) for a liquid phantom for all 
wavelengths of the probe.  
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Figure 5.3. An example of reconstructed absorption and reduced scattering coefficients for a liquid phantom 
(phantom #4 in Table 5.1) for all wavelengths in the probe. A. Absorption coefficient B. Reduced scattering coefficient 
We evaluated different phantoms to test the performance of the system. Table 5.1 lists 
the evaluated phantoms and the average error in absorption and reduced scattering 
coefficients considering all wavelengths for each phantom. Please note that μa and μ’s are 
different at each wavelength but in the table we only provide the expected values at 810 
nm to distinguish between the phantoms. The absolute average error for reconstruction 
of absorption coefficient was approximately 9.3 ± 6 % (error ± std) and the absolute 
average error for reconstruction of reduced scattering coefficient was approximately 4.5 
± 3 %, considering all wavelengths and all phantoms.  
Table 5.1. Phantoms used for SFDI probe evaluation 
Phantom # Expected μa  
@810 nm (cm-1) 
Average μa error 
for all λs (%) 
Expected μ’s  
@810 nm (cm-1) 
Average μ’s error 
for all λs (%) 
1 (ref) 0.0745 0.19 4.9056 0.22 
2 0.1293 2.40 4.9056 2.82 
3 0.1844 12.54 4.9056 5.74 
4 0.2387 3.87 4.9056 0.72 
5 0.0745 21.62 6.0829 2.86 
6 0.0745 9.82 6.8678 9.77 
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7 0.0745 13.66 7.5546 8.08 
8 0.0745 10.52 9.8112 6.43 
 
5.3.2. Human in vivo forearm  
In order to evaluate the performance of the system for imaging biological tissue, we 
imaged a volunteer’s forearm in vivo. Figure 5.4 shows the reconstructed absorption and 
reduced scattering coefficient maps for all nine wavelengths in the probe. Regardless of 
some demodulation noise remaining in the lower wavelengths, absorption and scattering 
values are within the expected range for skin. Also please note that tissue is not present 
close to the top right and bottom corner of the images. Figure 5.5 shows the scattering 
slope and scattering amplitude maps obtained from analyzing the data from all nine 
wavelengths. The reduced scattering coefficient at a wavelength λ can be expressed as  
𝜇𝑠
′ (𝜆) = 𝐴 𝜇𝑠
′ (𝜆0) (
𝜆
𝜆0
)
−𝐵
                                             (5.4) 
Here A and B (unit-less) are referred to as the scattering amplitude and scattering power, 
respectively. μ's(λ) is the reduced scattering coefficient at a given wavelength, μ's(λ0) is 
chosen to be an approximate value of the reduced scattering coefficient of 1% Intralipid 
solution at 800 nm (10 cm-1), λ is a given wavelength, and λ0 is 800 nm [19]. To form the 
scattering slope and scattering amplitude maps, we stack the reduced scattering 
coefficient maps of all wavelengths in a 3 dimensional matrix and fit the reduced scattering 
coefficient values on each pixel to Equation 5.4 and extract A and B for that pixel. Figure 
5.5A shows the scattering amplitude map and Figure 5.5B shows the scattering slope 
map and the obtained values are within the expected range. Spectral maps can provide 
valuable information for studying healthy vs diseased tissue.  
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Figure 5.4. Reconstructed absorption and reduced scattering coefficients of a human forearm in vivo for all 
wavelengths.  
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Figure 5.5. Scattering amplitude and slope maps of a human forearm in vivo A. Scattering amplitude map. B. 
Scattering slope map. 
5.3.3. Bovine ovarian tissue 
Absorption coefficient and reduced scattering coefficient maps in addition to photographs 
of two ex vivo bovine ovaries are demonstrated in Figure 5.6. The bovine ovaries were 
obtained from a local farm and the institutional oversight was waived. The images show 
the capability of reconstructing and differentiating values and heterogeneity of optical 
properties in biological samples ex vivo. The proposed low-cost and small SFDI system 
can be used for imaging cancer samples ex vivo and data acquisition from ex vivo cancer 
samples is an ongoing task.  
 
Figure 5.6 Reconstructed absorption and reduced scattering coefficients of two bovine ovarian tissues ex vivo.  
5.4. Summary  
We have developed a very low-cost, handheld, and multispectral SFDI probe that 
incorporates 9 different LEDs and all illumination and detection components in a small 3D 
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printed probe. The performance of the probe was evaluated using liquid phantoms made 
from Intralipid and Indian ink. The system was further evaluated by imaging human 
forearm in vivo and bovine ovarian tissue ex vivo. Evaluating the performance of the probe 
in classification and characterization of ex vivo cancer samples is an ongoing task. 
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6. Summary  
In this dissertation we have described our efforts towards low-cost, high contrast, and 
miniaturized optical imaging with potential applications in cancer imaging.  
In chapters two and three, we explained our efforts in developing laser diode based 
photoacoustic microscopy systems given that laser diodes are low-cost and compact 
potential substitutes of conventional light sources used in photoacoustic imaging. In 
chapter two, we developed a method to be able to have low-loss collimation and focusing 
of high power pulsed laser diode light for use in photoacoustic microscopy and 
demonstrated the ability to image vasculature on porcine ovarian tissue ex vivo. In 
chapter three, we developed a laser scanning laser diode based photoacoustic 
microscopy system that provides fast data acquisition and does not require mechanical 
sample scanning in addition to being low cost and compact. The capability of this system 
in imaging thin vasculature on porcine ovarian tissue ex vivo also reveals its potential for 
imaging and characterization of human cancer samples [1–3].  
In chapter four, we described the synthesis and evaluation of a porphyrin-based 
monomeric water soluble photoacoustic contrast agent for in vivo tumor imaging. The 
performance of the dye in improving tumor imaging was evaluated, revealing a strong 
enhancement of in vivo photoacoustic signal from implanted tumors in mice upon injection 
of the dye. The lack of toxicity, favorable filtering and bioaccumulation, and strong 
enhancement of the photoacoustic signal suggest the potential of this dye as a suitable 
photoacoustic contrast agent for improving photoacoustic cancer imaging [4,5].  
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In chapter five, we reported a very low-cost, handheld, and multispectral SFDI system 
that incorporates up to nine LEDs and all illumination and detection components in a small 
3D printed probe. The system was evaluated by reconstructing absorption and reduced 
scattering coefficients of phantoms, in vivo human forearm, and ex vivo bovine ovarian 
tissue. The results suggest the potential of the system for classification and 
characterization of ex vivo cancer samples.  Imaging and classification of human ex vivo 
cancer samples is an ongoing task [6]. 
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